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To synthesise the best available evidence for the diagnostic test accuracy of measurement of serum 
procalcitonin compared to serum C-reactive protein for suspected osteomyelitis and septic arthritis in 
hospitalised children and adolescents. 
 
Introduction: 
Measurement of serum C-reactive protein remains a routine investigation for the diagnosis of 
osteoarticular infection in children and adolescents. Measurement of serum procalcitonin has been 
shown to outperform C-reactive protein in adults with osteomyelitis and septic arthritis. Before 
procalcitonin can be considered as a potential replacement or additional test in children and 
adolescents, a systematic review and meta-analysis targeting this population is needed. 
 
Inclusion criteria:  
Original studies reporting on the diagnostic accuracy of procalcitonin and/or C-reactive protein in 
children and adolescents aged between one month and 18 years admitted to hospital with suspected 
osteoarticular infection were included, compared to at least one reference test. The reference test 
was defined as positive culture or polymerase chain reaction confirmation of a pathogen from blood 
and/or bone biopsy and/or joint fluid aspirate and/or at least two of the following: 1) purulent material 
from sterile site; 2) positive radiological findings consistent with osteoarticular infection; 3) symptoms 
and signs consistent with osteomyelitis and/or septic arthritis.  
 
Methods:  
JBI methodology for systematic reviews of diagnostic test accuracy was employed. Information was 
sourced from four databases; MEDLINE, Embase, Cochrane Central Register of Controlled Trials, 
and Web of Science and four grey literature sources; Mednar, OpenGrey, Google scholar and 
ProQuest Dissertations and Thesis. Only studies published in English were considered. The 
methodological quality of selected studies was formally evaluated and sensitivity and specificity data 
were extracted and 95% confidence intervals determined. Meta-analysis was performed to estimate 
summary points using a bivariate model and generate a hierarchial summary receiver operating 
characteristic curve (HSROC) with global measures of test accuracy performance including likelihood 




Eight out of 3086 studies were included in the final analysis. Four of these studies used a common 
CRP test threshold of 20mg/L for septic arthritis cases only. At this threshold the estimated pooled 
sensitivity of C-reactive protein was 0.86 (0.68-0.96) and the pooled specificity 0.9 (0.83-0.94). Using 
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a HSROC model from six studies including all osteoarticular infections, the diagnostic odds ratio for 
C-reactive protein was estimated to be 39.4 (14.8-104.9) with a positive likelihood ratio 5.3 (2.3-11.9) 
and negative likelihood ratio 0.1 (0.07-0.2). There were insufficient studies from this review to 
statistically evaluate the diagnostic accuracy performance of procalcitonin using meta-analysis.  
 
Conclusion:  
We have synthesised the best available evidence to evaluate the diagnostic test accuracy of serum 
measurement of procalcitonin and C-reactive protein in children and adolescents with suspected 
osteomyelitis and septic arthritis. Clinicians should continue to measure serum C-reactive protein as 
the preferred inflammatory marker in this setting and await more evidence before incorporating 
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Chapter one provides an outline of the thesis structure and context of this review. The research 
question is stated and the methodological basis for the research approach implemented is discussed. 
Finally, the rationale for performing this systematic review is provided along with the researcher’s 
background and expertise in this area. Based on the work from this thesis a systematic review 
protocol has been published and the findings from the completed systematic review has been 
accepted for publication.1 
 
 
1.1 Structure of the thesis 
 
This thesis has four chapters. Chapter one identifies the research problem, proposes the research 
question and then provides a pathway forward. Chapter two gives a detailed account of the 
methodology and methods employed by the researcher and in chapter three the results are 
presented. In chapter four the significance of the findings and implications in advancing scientific 
knowledge in this field is discussed.  
 
1.2 Context of the review 
 
Choosing Wisely is an initiative of the American Board of Internal Medicine Foundation launched in 
2012 that aims to encourage meaningful conversations between health care practitioners and clients 
to ensure that appropriate and quality of care in being provided.2 Specifically the goals are to promote 
interventions and investigations that are supported by evidence, not duplicative of other tests or 
procedures already received, free from harm and truly necessary. Choosing Wisely campaigns now 
exist throughout many countries.2 Choosing Wisely Australia is an initiative of the Australian National 
Prescribing Service Limited in partnership with Australia’s health professional colleges, societies and 
associations.3 A feature of this national campaign is to enable doctors to start important conversations 
about the use of laboratory tests in medicine with an emphasis on utilising evidence to demonstrate 
the benefits of, and/or highlight potential risks from, the ordering of medical tests. The Royal 
Australian College of Physicians, division of Paediatrics and Child Health have already commenced 
work on this by providing their fellows with recommendations around a small number of tests for 
children and adolescents. The Australasian Society for Infectious Diseases has also made a smaller 
contribution for infectious diseases testing in both adults and children. The recommendations from 
these professional organisations aim to be evidence-based, developed and approved using a 
transparent process and focused on tests that are cost-effective and/or are used frequently across our 
healthcare sector.  
 
While healthcare professionals have an important responsibility to ensure the tests they request are 
evidence-based and add value to their patient’s healthcare journey, the consumer can also play a 
significant role in this process. Engagement of consumers is to be encouraged by asking doctors for 
more information in five key areas: the need for any test; the risks associated with the test; the 
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availability of simpler or safer options; consideration of not having the test; and where relevant, the 
financial cost of the test. In Australia medical tests that are not listed on the Medicare Benefits 
Schedule are ineligible for government rebate making the cost of performing these more expensive to 
the individual or health care organisation. 
 
The Choosing Wisely Australia® campaign is in its early stages. It is too soon to determine if it will be 
successful in improving the patient experience of care by avoiding unnecessary tests and/or reducing 
financial cost to our healthcare system. Increasing awareness of this campaign and compliance with 
the key messages for both healthcare professionals and consumers will be essential for widespread 
implementation. 
 
For clinical doctors working in the public hospital system, the ordering of tests for prognosis, diagnosis 
and monitoring of treatment forms an integral part of their daily work. For doctors who are required to 
make rapid clinical decisions based on test results, the availability of onsite 24-hour laboratories 
processing these urgent tests is essential. 
 
At the Women’s and Children’s Hospital (WCH) in Adelaide, laboratory services are delivered by the 
South Australian government pathology service (SA Pathology) which provides both onsite and local 
laboratories for patients. 
 
In 2018, the WCH introduced and implemented a hospital wide “early sepsis recognition” program 
aimed to improve both the diagnosis and treatment of sepsis in children and women. As part of this 
program, a clinical protocol recommended doctors request the serum measurement of a new 
biological marker to aid in the diagnosing of sepsis, called procalcitonin (PCT). This new biomarker 
test has shown to be more sensitive and more specific for sepsis and serious bacterial infections 
compared to other routine inflammatory markers in use, including C-reactive protein (CRP). The 
recommendation for use of this test was based on published data from systematic reviews and meta-
analyses.4-9 SA Pathology agreed to provide this laboratory service using a rapid kit test at an 
estimated cost of approximately 10 times that of CRP. While the aim of the protocol was to restrict the 
use of PCT in patients with sepsis or suspected sepsis only, an unexpected and incremental increase 
in demand emerged from clinicians. It became apparent that PCT was being requested for infective 
conditions other than for patients with suspected sepsis. Without a hospital-wide governance process 
in place to monitor and restrict laboratory testing, combined with a lack of awareness of the messages 
from the Choosing Wisely Australia  initiative, PCT was being requested as an additional test for 
patients presenting across a wide spectrum of suspected paediatric infections. 
 
The clinical impression by the author is that children and adolescents presenting to hospital with 
suspected bone and joint infections represented one such cohort of patients where PCT was being 
requested outside the recommended sepsis protocol. The rationale for requesting PCT seems 
biologically plausible given the diagnosis of osteoarticular infections can be difficult and this test could 
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potentially improve the post-test probability of having an infection based on the evidence from its use 
in sepsis. Pressures on doctors resulting from any unnecessary delays in the diagnosis and/or the 
administration of effective antibiotic therapy may also be an important driver of this requesting 
behaviour given these infections can lead to permanent and severe sequelae  
 
As there is currently no single reliable and or readily available non-invasive test to confirm or exclude 
bone and joint infection, clinicians usually perform a cascade of diagnostic investigations. This usually 
begins with the least invasive and lowest risk tests being performed first and then progressing to more 
invasive tests and procedures to either confirm or exclude the diagnosis. Included in the preliminary 
investigation panel of routine blood tests is CRP.10 
The test accuracy of CRP in bone and/or joint infection has been recently established by two 
published systematic reviews and meta-analyses but in predominately adult subjects. Both of these 
studies suggest PCT may outperform CRP as a diagnostic test.11, 12 While this is encouraging for 
potential translation to the paediatric setting, to date there has not been a comprehensive and 
rigorous evaluation specifically in children and adolescents to guide clinicians as to the diagnostic 
accuracy and utility of PCT. It is therefore important to examine and carefully evaluate the evidence 
behind the local practice of ordering PCT in bone and joint infection in children and adolescents, 
before providing any formal recommendations back to WCH clinicians.  
 
The timing of the observed increase in PCT testing at the WCH provided an opportunity to engage 
and support the national Choosing Wisely initiative at an organisation level and importantly focus 
clinicians’ attentions towards improving laboratory stewardship with the review, assessment and 




The primary aim of this thesis is to synthesise and analyse the best available evidence for the 
diagnostic test accuracy of PCT compared to CRP for suspected acute osteomyelitis and septic 
arthritis in hospitalised children and adolescents. 
 
1.4 Osteoarticular infections in children 
 
In children and adolescents, bacteria can infect the bone and joints through a rich blood supply 
resulting in an acute inflammatory response termed acute haematogenous osteomyelitis (OM) when 
confined to bone, or septic arthritis if localised to the joint.13 In developed countries, OM rates vary 
from two to 13 per 100,000 children and is more common than septic arthritis.14, 15 Osteomyelitis 
affects twice as many boys as girls, while the male to female ratio for septic arthritis is 1.2/1.16, 17 In 
children and adolescents aged 16 years and under, the median age for OM is four years and one and 
a half years for septic arthritis.18 Although any bone or joint can be infected, OM and septic arthritis 
more commonly affect the lower limbs in children.13 
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The source of bacteria leading to infection is usually not clinically evident, suggesting colonization of 
the skin; however, oral or respiratory mucosa are the most likely portal of entry.19 Common pathogens 
identified in OM and septic arthritis in children and adolescents are Staphylococcus aureus, Kingella 
kingae, Streptococcus pneumonia and Streptococcus pyogenes, depending upon age, risk factors 
and geographical location.10, 14, 19, 20 Once infection is established in the bone or joint, a prompt 
cascade of inflammatory responses ensues, both locally and systemically, with release of various 
inflammatory factors.21, 22 Most children who receive early and appropriate therapy for OM and septic 
arthritis have no long-term sequelae.13, 23 A delay in treatment or inappropriate antibiotic choice 
however, can result in complications including disruption to bone growth, angular deformity of bone, 
cartilage destruction and unstable articular surfaces of the joints all of which can result in permanent 
damage.13, 23  
The clinical manifestations of OM can vary and frequently include acute, persistent and increasing 
pain over the affected bone, reduced weight-bearing, decreased range of movement, and fever.23 
Swelling or redness of the soft tissue over the affected bone may also be seen.13 Features of septic 
arthritis overlap with the above presentation findings in addition to specific swelling and erythema of 
the joint and pain on movement of the isolated joint.19  
At present there is no single error free diagnostic test that can confirm or rule out OM and or septic 
arthritis irrespective of the patient’s age.14 Diagnosis continues to require a combination of careful 
history, thorough physical examination, radiological imaging, laboratory blood tests and 
microbiological sampling for suspected bacterial pathogens.14 While conventional x-rays are the first 
imaging study performed, they are frequently negative for both septic arthritis and early OM.14 Classic 
bone changes of OM involving long bones may not be apparent on x-ray until 10-21 days of 
infection.21 Ultrasound can detect excess fluid in large joints such as the hip with a sensitivity of 95% 
and identify collections in subperiosteal areas of bone, if present, with a sensitivity of 55%.19, 23, 24 
Magnetic resonance imaging (MRI) is now the most accurate imaging tool for OM with excellent 
sensitivity (98%) and specificity (92%).25 It is however relatively expensive, not universally available, 
and requires sedation or anaesthetic for younger children.23  
Laboratory blood tests commonly requested include examination of the total and differential white 
blood cell (WBC) count, erythrocyte sedimentation rate and CRP. For septic arthritis, microbiological 
sampling of synovial fluid is routinely collected for cellular microscopy, Gram stain, culture and 
bacterial polymerase chain reaction (PCR). In children this is usually performed during therapeutic 
treatment with joint drainage under general anaesthesia.10  
For uncomplicated OM in children and adolescents however, bone aspiration and/or biopsy to identify 
bacteria is not routinely performed as it is invasive with associated risks and may not have any 
therapeutic benefit.10 Infection in both OM and septic arthritis is usually haematogenous spread in 
paediatric patients and blood cultures are often collected, with a causative pathogen identified by 48 
hours in 10% to 40% of cases.10, 16 
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While there appears to be variation in the definitions of reference standards for OM and septic arthritis 
in children and adolescents in the published literature, the isolation of a microorganism from the bone, 
joint and or blood (with a compatible clinical or radiological syndrome), has been proposed as the gold 
standard in a recent international paediatric bone and joint infection guideline.10 This definition is 
consistent with other published findings.26-28 However, routinely applying this gold standard for all 
suspected cases may be associated with increased risk from potential harmful operative procedures, 
may be more expensive, or not readily available and may not improve the diagnostic yield.29 
Therefore, by using less stringent criteria for the gold standard test by excluding isolation of an 
accepted pathogen for OM, this approach better reflects actual clinical practice, see section 2.3.3 for 
details.18, 30, 31 
While OM and septic arthritis can be found as separate conditions in the published literature, from a 
clinical perspective concurrent infection involving adjacent bone and joint is well described in children 
and adolescents, and investigators often evaluate them together as a single condition.13, 18, 19, 28 
Studies using MRI suggest concomitant bone and joint infection may occur far more frequently than 
clinically suspected and in more than one third of paediatric cases.32, 33  
It is important for clinicians to make timely decisions regarding the diagnosis and treatment of OM and 
septic arthritis given the potential for serious sequelae. While essential, the clinical history and 
examination findings cannot always reliably differentiate infective from non-infective causes of bone 
and joint pathology in children. Furthermore, the initial radiological imaging requested may be normal, 
and invasive biopsy procedures for specimens when performed take time to process. Specimens 
taken for microbiological culture of pathogens are positive only in approximately half of cases and 
results can take up to 24 hours or longer.34 35 Identification of pathogens using Polymerase Chain 
Reaction (PCR) techniques in the microbiology laboratory is a more rapid process, but not universally 
available to most clinicians for bone and joint infections. 
Total WBC count however is a rapid and easy test to perform either manually or by automated 
counter. Unfortunately it is an unreliable marker of infection as WBCs are elevated in only 36% of 
children with OM, and 30% with septic arthritis can have a normal WBC count.14, 21, 36 Consequently, 
clinicians rely on more accurate non-invasive and rapid laboratory investigations such as CRP which 
is routinely performed.16, 27   
1.5 The biology and use of C-reactive protein serum measurement 
 
Measurement of serum CRP is one of the most frequently requested inflammatory biomarker tests in 
paediatric clinical practice.37 It was discovered from human serum during the acute phase of 
streptococcal pneumonia infection in 1930 and received this name because it reacted with the C-
polysaccharide of pneumococcus bacteria to form a precipitate.38 CRP was the first acute phase 
protein to be described and is a sensitive systemic marker of tissue damage, infection and 
inflammation.39 It is a highly conserved plasma protein synthesized by hepatocytes in the liver and is 
primarily induced by proinflammatory cytokines released locally at the site of the tissue damage, 
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infection and/or inflammation but also from systemic release.39 Interleukin-6 appears to be the main 
cytokine regulator driving transcription of CRP protein and is reinforced by other pro-inflammatory 
cytokines including IL-1 B and tumour necrosis factor.40 
Human CRP once released into the circulation, binds with highest affinity to extrinsic phosphocholine 
residues expressed on cell wall surfaces of bacteria, fungi and parasites as well as plant products. 39 
When CRP is bound to these macromolecular ligands it is recognised by C1q and activates the 
classical complement pathway via C3 leading to opsonisation and phagocytosis of invading 
pathogens.39 Both immunoglobulin G and FcR receptors expressed on numerous cell surfaces 
including macrophages and lymphocytes can recognise CRP and this aggregation may trigger 
proinflammatory mediators with further immune cell recruitment, modulation and activation.40  
In healthy young adults the median serum concentration of CRP from one study was 0.8 mg/L, with a 
99th percentile of 10mg/L.39 Reporting of the 97.5th percentile for measurement of serum CRP in 
children ranged from 2.8 to 6.3 mg/L in two to 10.9 year old boys and girls.41 A higher 97.5th 
percentile level of 11.3 mg/L was reported in a Swedish study in children between the age of 6 
months and 18 years.
42  
Following an acute phase stimulus, CRP rises 4-6 hours later duplicating every eight hours from 
baseline until peaking at 36-50 hours.38 The plasma half-life is 19 hours and is constant under all 
conditions of health and disease so that the sole determinant of CRP concentration is the rate of 
synthesis.39  
Levels of CRP in the plasma rise in proportion to the intensity of the pathological or inflammatory 
insult.43 Markedly, elevated levels are more often associated with bacterial infections rather than viral 
aetiologies and CRP levels can reach up to 1,000 fold.44 Elevated CRP levels however are not 
specific and found in non-infectious states including autoimmune disorders, inflammatory diseases, 
malignancy, trauma, burns, and myocardial infarction.45 When the infection stimulus for CRP 
production falls and ceases following appropriate therapeutic interventions such as antibiotic therapy 
and/or operative treatment, the serum concentration falls at almost the rate of plasma CRP 
clearance.39 
C-reactive protein has been used to assist with the diagnosis of bacterial osteoarticular infections in 
children and adolescents for decades.36 A systematic review of haematogenous acute and subacute 
paediatric osteomyelitis from 2012, found CRP was abnormally elevated on presentation in 80.5% 
cases and 100% with concomitant septic arthritis; however, no formal meta-analysis on the test 
characteristics of CRP was performed.23 For isolated septic arthritis, CRP has shown to be a strong 
biomarker for diagnosing septic arthritis of the hip in the paediatric setting, while others have 
suggested the value of CRP measurement may be better as a negative predictor (that is a “negative” 
result for this test may be more informative to exclude infection rather than to confirm it with a positive 
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result).27, 46 More recently, the usefulness of CRP in diagnosing long bone osteomyelitis in children 
has been questioned.47  
The popularity of CRP measurement to assist in the diagnosis of bone and joint infections in children 
and adolescents without robust systematic analysis of its test performance characteristics, may be 
attributed to familiarity from use, inexpensive cost, rapid turnaround time, predictable kinetics and 
possible bias given its usefulness for prognosis, monitoring treatment response and guiding the timing 
of intravenous to oral antibiotic stepdown therapy.18, 28 
While the general consensus seems to favour inclusion of serum measurement of CRP in the 
investigation of osteoarticular infections, a systematic review and meta-analysis focusing on the 
overall diagnostic accuracy in children and adolescents will contribute towards a better understanding 
of the benefits and limitations of this test and clinical utility in the paediatric setting. This information 
will also facilitate formal comparison with more novel inflammatory markers of bacterial infection in 
this setting including serum measurement of PCT. 
1.6 The biology and use of serum Procalcitonin measurement 
 
Procalcitonin is a 116 amino acid peptide and precursor of the hormone calcitonin and has recently 
emerged as more specific biomarker for bacterial infection in the paediatric setting.48 The precise role 
which PCT plays in the immune response to inflammation is unknown. One study has shown that 
PCT is a potent amplifier of the inflammatory cascade by increasing expression of surface markers on 
leukocytes, increasing cytokines and augmenting nitric oxide production.49 Other studies however 
have demonstrated that it may neutralise bacterial lipopolysaccharides and reduce both the 
phagocytic activity of neutrophils and their ability to migrate towards chemo-attractants.50, 51 
 
Production of PCT can be activated in all parenchymal tissues in response to bacterial, fungal and 
some parasite infections mediated by cytokines interleukin-6, tumour necrosis factor and interleukin-
1B.48 Conversely, PCT is attenuated by interferon- primarily released in response to viral infection.48  
 
Procalcitonin synthesis is detectable in serum approximately two hours after onset of infection and 
increases promptly upon stimulation via cytokine production.52 Peak PCT levels occur within 48 hours 
and can increase to more than 400 times baseline levels.53 54 Procalcitonin has a half-life of 
approximately 24 hours 48 and levels also correlate with the extent and severity of inflammation.55, 56 
The highest serum levels of PCT however are usually seen in acute systemic bacterial infection and 
sepsis.57 
 
Procalcitonin measurement therefore has some advantages over CRP with a more rapid kinetic 
profile, increasing earlier in response to infection, peaking quicker and showing faster decline with 
resolution of infection.48 Serum PCT levels in healthy individuals are exceedingly low and rise in 
response to the severity of systemic infection; early and or more localised infections however may 
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result in smaller increments of PCT elevation.48, 58 Levels of PCT can also be elevated in other non-
infective conditions including the first 48 hours of neonatal life, following major surgery, trauma, burns, 
and cardiac shock.58  
 
Quantification of serum PCT can be performed easily using commercially available automated assays 
or more rapid point of care test kits.48 The concentration of PCT from the serum of healthy individuals 
is typically less than 0.1 ug/L.48, 52, 59 Numerous algorithms have been published using serum PCT 
measurement across different threshold values (0.05ng/mL-9.33ng/mL) to assist clinicians in the 
diagnosis of various infectious conditions.52, 53, 59-61 
In the paediatric published literature, evidence obtained from systematic reviews and meta-analyses 
support the use of PCT as a routine test where serious bacterial infections may be suspected, but 
without an apparent source,8, 9, 62, 63 with PCT outperforming CRP.8, 63 Procalcitonin has also 
demonstrated similar advantages in neonatal sepsis showing better diagnostic accuracy than CRP for 
bacterial infection.64, 65 Use of serum PCT measurement in other paediatric infections is expanding 
and includes urinary tract infection, pneumonia, febrile neutropenia as well as bone and joint 
infections.58  
1.7 Statement of the review question 
 
What is the diagnostic test accuracy performance of serum measurement of PCT compared to CRP in 
patients aged between one month and 18 years, admitted to hospital with suspected acute 
osteoarticular infection? 
 
1.8 Overview of knowledge synthesis 
 
Knowledge synthesis is the assembly of parts into a new whole, that organises, interprets the 
concepts, connections, controversies, and constraints of a body of literature filling in gaps, and 
generating new insights, perspectives, directions and novel explanations about a defined research 
topic.66 Traditionally this would involve an authoritative expert in a specialised field publishing a 
narrative review to provide recommendations supported by subjectively chosen evidence.67 In the 
1960’s knowledge syntheses were common within social sciences, education and psychology, 
however the widespread application and demand for evidence synthesis in medicine soon followed.68  
 
While many models of knowledge synthesis exist, in the healthcare setting systematic reviews 
evolved focused on rigorous methodology originally developed by the Cochrane Collaboration. This 
synthesis consists of a clearly formulated question and the use of systematic and explicit methods to 
identify, select, critically appraise and extract and analyse data from relevant research.69 What 
fundamentally sets systematic reviews apart from the traditional narrative reviews are the formal 
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methods aimed to minimise risk of bias and increase the reliability and accuracy of the conclusions 
drawn.67 
 
Systematic reviews are the gold standard to search for, collate, critique and summarise the best 
available evidence regarding a clinical question.70 They are also regarded as the pillar of evidence- 
based health care.70 There are a number of fundamental steps in performing a systematic review and 
these have been well described in the published literature.71 Determining the appropriate type of 
systematic review first requires careful consideration of the research question. Formulating the 
relevant questions typically found in an effectiveness review requires a structured approach and 
includes basic elements such as the population(s) of interest, the intervention(s), the comparison(s) 
and the outcome (s).72 To improve the value of the systematic review, the study question ideally 
should be clearly and completely defined and should be clinically important with sufficient uncertainty 
or debate in the literature.73 
 
Once the need for a systematic review has been established, the next step is to define the objectives 
using a priori protocol specifying the explicit methods that will be used to guide this process. This 
includes a detailed description of the methods used to search, retrieve, appraise the literature and 
how the data is to be extracted, synthesised and analysed. This should follow the Preferred Reporting 
Items for Systematic reviews and Meta-analysis Protocols (PRISMA-P) guidelines.74 The purpose of 
these guidelines is to decrease the likelihood of bias from post hoc changes and analyses and 
selective reporting in the review.69 They also help to facilitate reproducibility of the findings.67 
Publication of the protocol in a peered review journal and registration of the protocol in the 
International Prospective Register of Systematic Reviews (PROSPERO) data base increases 
transparency and reduces unnecessary duplication of any work already being done on this topic.67 
 
For systematic reviews, the aim of the search strategy is to find all of the available evidence that can 
be used to answer the particular question proposed.75 Therefore the search strategy should be as 
comprehensible and as inclusive as feasible. For clinical questions this usually includes searches of 
all of the major electronic data bases for both published literature as well as the unpublished grey 
literature to help minimise publication bias.69 The search strategies recorded should be replicable to 
allow updating and repeating by other researchers. 
 
The next step is the selection of relevant studies to address the research question. This is usually 
conducted by first screening by title and abstract of the citations and then a second screen is 
performed in detail by examining the full text articles using predetermined criteria for eligibility and 
inclusion. Reasons for excluding full text studies are documented for transparency and reproducibility. 
 
Included studies are assessed by two reviewers to evaluate the methodological quality of each study. 
The validity of the results of the systematic review will greatly depend on the risk of bias in the 
individual studies.69 This process is standardised using published validated tools depending upon the 
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type of systematic review.67, 73 Quality assessment using the instruments available however still 
requires subjective judgment by the assessor and disagreements may require a further reviewer to 
assist in reaching a conclusion.76 The results of quality assessment are best summarised in table or 
graphical format to provide readers with an overall impression of the quality of the data and help 
assess the effect of any bias on the results.75 
 
Finally, the data is extracted and synthesised. All data to be extracted from individual studies should 
be clearly defined in the protocol and can be recorded using specific data extraction tools.69 This 
information can then be abstracted into a single database. Synthesis and analysis of the evidence is 
dependent upon the question being asked and the variables collected. For quantitative data this may 
or may not include meta-analysis. 
 
Meta-analysis is a statistical method for combining the results of multiple independent primary studies 
that address the same question to produce a pooled or summary quantitative estimate of the outcome 
of interest.77 A key benefit of this approach is the aggregation of quantitative data which may lead to 
higher statistical power and a more robust point estimate with greater precision than is possible from 
the measure derived from any individual study (providing the studies are of equal level of evidence). 78 
If meta-analysis is not found to be feasible, most commonly from heterogeneity and/or studies being 
thought to be too different, then a structured systematic review process may still provide a more 
objective appraisal of the available evidence than a traditional narrative review. 79 
 
In addition to the statistical advantages provided, a systematic review with a meta-analysis approach 
may better establish the generalisability of scientific findings as multiple studies provides an 
interpretive context not available from single studies.80 Furthermore consistency and inconsistency is 
more easily observed across individual studies using this approach.78 High quality systematic reviews 
can also define the boundaries of what is known and gaps in current understanding that may help 
determine the direction of future research.81 
 
Systematic reviews and meta-analysis of diagnostic test accuracy aim to summarise the test accuracy 
performance of an index test(s) with a reference or gold standard. Diagnostic test outcome measures 
relevant to clinical practice usually include sensitivity, specificity, likelihood values and receiver 
operating characteristic curves. This information is important to clinicians and other healthcare 
professionals to make informed decisions regarding the optimum test use in practice.82 While the 
approach outlined above remains this same for diagnostic test accuracy reviews, there are some 
unique study characteristics that require a modified approach. For this reason the Preferred Reporting 
Items for Systematic reviews and Meta-analysis (PRISMA) statement was extended and published as 
the PRISMA-DTA to help guide researchers improve the quality and consistency of diagnostic test 
reviews.71 PRISMA-DTA addresses several detailed and specific test related requirements that are 




1.9 Rationale for this systematic review/meta-analysis 
 
The rationale for evaluating both index tests in this systematic review and meta-analysis was to 
provide clinicians with evidence regarding the performance of the routine measurement of CRP 
compared with measurement of PCT. This would be an essential prerequisite for any future 
recommendation around the use of these diagnostic tests in practice at the WCH and other similar 
health care settings. As OM and septic arthritis frequently co-exist in children and adolescents, it was 
considered clinically relevant to evaluate the diagnostic accuracy of PCT for both conditions into a 
single systematic review and meta-analysis.  
 
While consideration was given to conducting a diagnostic study to compare both diagnostic tests 
directly in our local health setting, a systematic review was considered to be a quicker and less costly 
pathway to achieve the desired outcome.78 Even if an additional single diagnostic accuracy study 
could be performed for CRP and PCT, the results seen may not be representative of the overall test 
performance and the recommendations may be erroneous. 83 Causes of variation when evaluating 
sensitivity and specificity of diagnostic test outcomes has been well documented and includes, 
random chance, differences in thresholds for test positivity, deficiencies in design and conduct, 
diversity of settings and population, and unexplained variation.76 Biased results can lead to poor 
recommendations regarding test accuracy performance and may affect patient outcomes. 83 
Undertaking a systematic review with meta-analysis approach may better establish the 
generalisability of the performance of both index tests and identify the direction and magnitude of 
outcome measures, providing of course there are sufficient studies to be included. It may also help 
identify inconsistencies or conflicts from observed any outcome measures.76 
 
Based on the research question proposed, a systematic review of diagnostic test accuracy was 
considered to be the most appropriate methodology to evaluate the test performance outcomes of 
both CRP and PCT.70 
 
A preliminary search of MEDLINE, Cochrane Database of Systematic Reviews, and the JBI Database 
of Systematic Reviews and Implementation Reports was conducted as a first step to identify any 
previously published systematic review with meta-analyses on this topic. This resulted in identifying 
two systematic reviews with meta-analyses examining the diagnostic performance of PCT in 
osteoarticular infections. In both of these studies the authors conclusions favoured PCT over CRP as 
a diagnostic test.11, 12 In the first published study from 2013 examining bone and joint infections, of the 
seven studies evaluated, only two included children, with conflicting results.11 While the investigators 
included all children, variability in and compliance with the gold standard or reference test was 
observed. Furthermore, errors associated with the referencing numbers in citing of the paediatric 
papers permitted the possibility of misinterpretation of their overall findings. 
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In the second published systematic review and meta-analysis from 2017, ten studies examining septic 
arthritis cases only were included in the final analysis to assess the diagnostic accuracy of PCT.12 The 
same two paediatric papers as reported in the initial review above were included, and one of these 
papers was incorrectly classified and included in the statistical analysis as an adult study. 
Furthermore, inconsistencies regarding the inclusion study flow chart and concerns of a limited search 
strategy, potentially biased the outcomes of their findings.84 Both of these systematic reviews 
searched PubMed, Embase and the Cochrane Library, but a grey literature search was not 
performed. On further searching, a proposed systematic review of serum PCT levels as a diagnostic 
marker of joint infection was found registered in PROSPERO.85 Upon contact with the registering 
author by email, this review had not and was unlikely to progress. 
 
A subsequent but limited exploratory search for individual publications in the paediatric literature 
revealed fewer PCT diagnostic test accuracy studies with smaller patient numbers compared to CRP. 
Furthermore, most of the studies did not evaluate both CRP and PCT directly to the reference test in 
a single patient. The most feasible pathway forward to increase sample sizes and optimise the power 
and precision of any future estimates of diagnostic test accuracy of both tests was considered to be a 
new systematic review with meta-analysis.81 In addition emerging network meta-analysis techniques 
were considered to be potentially useful by allowing studies using only one index test to be included 
and compared indirectly to the reference standard. It was ascertained that providing trials included 
were sufficiently similar, using this methodology should further increase the probability of including 
more eligible studies into the final formal pooled meta-analysis.86 
 
1.10 Researcher’s experience in this field 
 
The researcher is a paediatric infectious diseases specialist, currently working within the Infectious 
Diseases Department at the WCH in Adelaide, South Australia. Between 20% and 25% of his current 
inpatient consultative workload involves working with orthopaedic specialists in the microbiological 
diagnosis and antimicrobial management of acute osteoarticular infections in children and 
adolescents admitted to hospital. As this type of clinical work involves frequent use of routine tests, it 
is important that both disciplines remain up to date and consistent with an agreed approach and 
where possible use the best available evidence on which to make recommendations regarding 
practice change. While the researcher has not published in this specific field, he has accumulated 
sufficient experience in this area to provide a level of understanding and clinical perspective for such 
a review. Having had exposure to both CRP and more recently PCT testing in our facility, the results 









Clinicians have a responsibility to ensure their request for performing measurement of PCT from an 
individual patient is evidence-based for their specific indication. There is sufficient uncertainty as to 
the value of measuring PCT in children and adolescents presenting to hospital with osteoarticular 
disease. Examination of the available scientific literature to answer the research question may be best 




2 Systematic review protocol 
2.1 Introduction  
 
Chapter two provides the protocol framework for this systematic review. A detailed description of the 
essential inclusion criteria for study selection is first provided. This is followed by the search strategy 
steps employed in accordance with the JBI methodology for systematic reviews of diagnostic test 
accuracy and documentation of the information sources searched.82 The process of study selection, 
assessment of study quality and data extracted is then provided. Finally, the methods for data 
synthesis and analysis, and for assessing certainty of the findings will be described.   
The process follows an a priori protocol was published in JBI Evidence Synthesis and registered in 
PROSPERO, number CRD42019140276. 1 
 
2.2 The review objective 
 
This objective of this systematic review was to identify, evaluate, extract and synthesise the best 
available scientific evidence to determine the diagnostic test accuracy of serum measurement of PCT 
compared to CRP in children and adolescents aged between one month and 18 years, admitted to 
hospital with suspected osteoarticular infection. 
 




Participants were children aged one month to 18 years admitted to hospital for suspected bone and/or 
joint infection. Studies reporting on both adults and children and where the data were reported 
separately for each group, were included. Patients with chronic osteoarticular infection and/or who 
were immunocompromised for any reason were excluded. 
 
2.3.2 Index Tests 
 
Original studies that measured, reported on and evaluated the diagnostic accuracy of both PCT and 
CRP index tests in the same group of participants and studies that tested only one biomarker were 
evaluated. There was no limitation based on the test methodologies used for the different 
commercially available index tests. 
 
2.3.3 Reference Test 
 
This review considered studies that defined the reference standard for OM and/or septic arthritis as: 
a) a positive bacterial culture or PCR conformation of an accepted pathogen from blood, biopsy or 
aspirate and/or  
b) having at least two of the following criteria: 
i) purulent material from biopsy or aspirate specimen,  
ii)  positive radiological findings consistent with osteoarticular infection, or 
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iii) signs/symptoms consistent with OM/septic arthritis 
 
2.3.4 Diagnosis of Interest 
 
Studies where the diagnosis of interest was acute presumed haematogenous OM and/or septic 
arthritis were considered in this review. 
 
2.3.5 Types of studies 
 
This review considered any quantitative design study published in the English language that 
examined the diagnostic accuracy of serum measurement of PCT and or CRP for OM or septic 
arthritis where the participant had one or both index tests and reference test performed. 
 
2.3.6 Types of outcomes 
 
Any English language study that quantified the diagnostic test accuracy of measurement of PCT 
and/or CRP (sensitivity and specificity) compared to the reference standard for OM and septic arthritis 
was considered.  
 
2.4 Review Methods 
 
This systematic review was conducted in accordance with the JBI methodology for systematic reviews 
of diagnostic test accuracy and also compliant with the recommendations outlined in the PRISMA-P 
and PRISMA-DTA guidelines.74, 82, 87 
 
2.5 Search strategy 
 
A comprehensive three-step search strategy was first performed on the 30th July 2019, to locate both 
published and unpublished studies written in English. The initial limited search (stage 1) was 
undertaken in MEDLINE (PubMed), followed by an analysis of text words contained in the title and 
abstracts, and of the index terms used to describe articles. This informed the development of a 
comprehensive search strategy that was adapted for each additional data base searched (stage 2). 
This search strategy is shown in Appendix 1. The reference lists of all studies selected for critical 
appraisal were also screened for any additional eligible studies not previously identified (stage 
3). Unpublished studies and grey literature were also included.  
 
2.5.1 Information sources 
 
The databases and platforms searched included:  MEDLINE (PubMed), Embase (Ovid), Cochrane 
Central Register of Controlled Trials (Ovid) and Web of Science. Sources of unpublished studies and 
grey literature searched included Mednar, OpenGrey, ProQuest Dissertations and Theses and 
Google Scholar. The search statements used for each database are detailed in Appendix 1. 
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2.5.2 Study selection 
 
Following completion of the search strategy, all identified citations were collated and uploaded 
into EndNote version X9 (Clarivate Analytics, PA, USA) and any duplicates removed. Titles and 
abstracts of individual studies were initially screened for suitability against the inclusion and exclusion 
criteria for this systematic review. All potentially relevant studies were then retrieved in full text. All full 
text articles were formally assessed in detail for eligibility against all of the inclusion/exclusion criteria 
in section 2.2. Reasons for exclusion of any full text study that did not meet the inclusion criteria were 
recorded and are reported in Appendix 2.  
 
2.5.3 Assessment of Methodological Quality 
 
Citations of selected studies after the full text review, were imported into the JBI System for the 
Unified Management, Assessment and Review of Information (JBI SUMARI). Two independent 
reviewers critically appraised each study for their methodological quality. This was based on ten 
signaling questions from the revised Quality Assessment of Diagnostic Studies (QUADRAS-2) critical 
appraisal tool for diagnostic test accuracy.88 The four domains used to assess risk of bias included 
patient selection (questions 1-3), index tests (questions 4-5), reference standard (questions 6-7) and 
flow and timing (questions 8-10). Disagreements between the reviewers was resolved through 
discussion. The combined reviewer results from the critical appraisal process were exported directly 
from JBI SUMARI in tabulated format with a yes, no or unclear response to the questions from each 
study. Concerns regarding applicability of the included studies was also assessed. Judgements with 
respect to patient selection (severity, demographics, comorbidities, setting), index test (variation in 
technology, execution, interpretation) and target condition (matching review question population) were 
reported. A summary critical appraisal table of bias and applicability for each study was then 
constructed. 
 
2.5.4 Data Extraction 
 
The data related to the diagnostic test accuracy of the index tests being investigated were extracted 
using a standardised tool.82 Sensitivity and specificity were chosen as principle discriminative 
measures of diagnostic accuracy for both index tests in this review. Data were extracted from all 
included studies either directly where 2 x 2 tables were provided or indirectly, using the raw numbers 
to construct the contingency table. Index test threshold levels were also extracted from each included 
study and where common thresholds were identified, the outcomes were evaluated using meta-
analysis. Additional data extracted included the country where the study was performed, year of 
publication, basic patient demographic characteristics (e.g. age range), target and comparator 
conditions, clinical setting, study design and funding sources. 
 
2.5.5 Data Synthesis 
 
A statistician was consulted to assist with the statistical synthesis and analysis component of this 
systematic review. All statistical data analyses were performed using STATA version 15.0 (Stata 
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Corp, College Station, Texas, USA). This included presentation of sensitivity and specificity data, 
likelihood ratios (LR), odds ratio (OR) and predictive values with their respective 95% confidence 




A random effects meta-analysis was performed in STATA where more than three studies for each 
index test reported on the same outcome. This was to provide sufficiently diverse data for statistical 
convergence in STATA modelling. Where meta-analysis was performed, sensitivity and specificity 
results were graphically displayed. For those diagnostic tests sharing a common threshold level, a 
Forest plot was generated and where thresholds varied a hierarchical summary receiver operating  
(HSROC) curve was displayed. Results of all meta-analyses were presented with 95% CIs.  
 
The magnitude of heterogeneity was reported qualitatively as depicted graphically from the Forest 
plots and by the degree of closeness of the scattered observed study results from the HSROC curve. 




The protocol for this systematic review was published and registered in PROSPERO prior to 
knowledge of all of the available studies. This was important to minimise author bias at each step of 

























Chapter three provides the results from the systematic review and meta-analysis. The first section 
describes the outcome of the search with a description of the studies found. The middle section 
evaluates the methodological quality of the included studies and the final section provides the findings 
of the review including statistical analysis.  
 
3.2 Description of Studies 
 
3.2.1 Search and study selection process 
 
A total of 3,086 articles were identified through the systematic search strategy conducted for each of 
the information sources documented (see Appendix 1). No other records of information were sourced. 
After removing 913 duplicates, a total of 2,173 articles remained. From screening of title and abstract 
only, a total of 2,072 records were excluded leaving 101 articles to be retrieved in full text. Following a 
detailed examination of full text, a further 93 records were excluded leaving eight published studies 
meeting all the inclusion and exclusion criteria. A flow chart of the search and study selection process 
is presented in Figure 1. The reason for exclusion of full text records have been categorized and 
summarised in Table 1. Refer to Appendix 2 for full citations of the 93 articles with individual reasons 
for their exclusion.  
 
Table 1. Reasons for exclusion of records. 
Reasons for exclusion Number of articles 
Summary, review or guideline article 14 
Insufficient data provided for accuracy test 11 
Language other than English 11 
Not a diagnostic test study 10 
PCR or PCT not included 8 
Sensitivity only provided 8 
Included neonates and data not analysed separately 5 
Included adults and data not analysed separately 8 
Not limited to bone and joint infection 7 
Reference standard not meeting criteria  5 




















































Records identified through 
database searching 
(n=3086) 
   
   



































Additional records identified through 
other sources 
(n=0) 











Full-text articles excluded, 
with reasons 
(n=93) 
Studies included in final 
synthesis 
(n = 8) 
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3.2.2 Characteristics of included studies 
 
All of the eight studies in this review were published in peer reviewed medical journals.31, 46, 90-95 The 
sample sizes varied from 33 to 313 with a total of 1,520 participants. As anticipated from the 
reference test criteria of bone and joint infection documented in the protocol, differences were 
observed in the reference test across the eight studies. Furthermore, there was no uniform 
consistency with the index test thresholds applied in these studies. Only two studies used a paired 
study design comparing both index tests (CRP and PCT) directly with the reference test in an 
individual patient.31, 93 The key characteristics of each included study are summarised in the included 
studies table  
(Table 2).  
 
3.2.2.1 Studies including CRP and reference test 
 
Five studies included an evaluation of the measurement of serum CRP in septic arthritis of the hip in 
children and adolescents.46, 90-92, 94 These five studies were relatively uniform with respect to the 
population, clinical context, hospital setting and the index test. The test threshold for CRP was set at 
20mg/L for CRP for four of these studies.46, 91, 92, 96 In the remaining study the cut off was 10mg/L.94 
Variability between and within these studies with respect to the reference test was noted as not all 
patients received the same investigations. All studies were conducted in specialised tertiary hospitals 
with paediatric expertise. Only one article of the five was a prospective study.46 The studies were all 
consecutive cohort selected cross sectional design, that is patient selection was based on suspicion 
of joint infection in these cases. Tables providing raw data for calculation of diagnostic test accuracy 
outcomes were available in four studies.46, 91, 94 96 The remaining study required extraction of data 
from the text in the results section.92 Participant numbers varied across the studies 33 to 311. Studies 
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3.2.2.2 Studies including both CRP and PCT and reference test 
 
Two studies in this review evaluated both CRP and PCT directly with the reference test.31, 93 Both 
studies were prospective using a consecutive cohort selected cross-sectional study design.  
In the smaller study from South Africa a total 33 children and adolescents with suspected bone and or 
joint infection were enrolled. This study used cut off of 10mg/L for CRP and 0.2 ng/mL for PCT 
threshold. 93 The hospital setting was similar to those studies above. 
In the larger of these two studies from France a total of 339 patients presenting to a university 
teaching hospital with presumed osteoarticular infection were included.31 In this study, a PCT serum 
measurement of 0.5 ng/mL was chosen as the threshold level. While CRP was also measured, it was 
also included to identify patients categorized as “suspected infection”. For this reason CRP could not 
be evaluated as a diagnostic marker in this study. Four cases that included using CRP in their 
reference standard to classify patients as suspected infection were therefore excluded from data 
analysis. The paired index study flow is shown below. 
 
 
Figure 3. Representation of study flow for both CRP and PCT 
 
3.2.2.3 Studies including PCT and reference test 
 
One study evaluated the index test PCT only with the reference test. 95 This study from China 
included children with acute and non-acute osteomyelitis.31 This was a prospective trial, involving a 
total of 187 patients. Patients with acute osteomyelitis were classified on layered bone structure 
radiologically with or without bone biopsy as the reference test. A cut off level of 3.56 ng/mL for PCT 
was not predetermined. Inconsistent use of the SI units for the PCT test was noted in this paper. A 
single index test study flow design for PCT is shown below. 
 








Figure 4. Representation of study flow for PCT 
 
3.3 Methodological Quality of Studies 
 
All studies were evaluated individually for bias across the four domains below. With the exception of 
the flow and timing domain, applicability was also included as part of the quality assessment. 
 
3.3.1 Patient selection 
 
In one study the enrolment was unclear.94 All remaining studies appeared to enrol patients 
consecutively. Two studies used a case-control design.91, 95One study excluded patients after being 
enrolled. 91All studies were of low concern regarding to the applicability of patient selection and those 
targeted by the review question. 
 
3.3.2 Index test 
 
Information regarding blinding from test results was provided in only one study and this was 
considered appropriate 93 Potential bias from blinding was considered unclear in the remaining 
studies. Three studies did not include a prespecified threshold for the index test being evaluated, 
potentially overestimating of the test performance outcomes in these cases.93-95 Low concern with the 
applicability of the index tests used in the studies was raised. 
 
3.3.3 Reference test 
 
While some variation with the reference standard was noted, they were all assessed by the two 
reviewers to correctly classify the target condition of interest. No study included information as to the 
reference standard being interpreted without knowledge of the index test result. The target condition 
defined in the reference question was consistent with that defined by the individual studies and low 
concerns regarding applicability of the reference test was therefore recorded.  
 
3.3.4 Flow and timing 
 
One study reported on the time interval between index test and reference standard and this was 
noted to be appropriate.31 The time interval was unclear in the other seven studies. Three studies 
reported using the same reference standard for all patients therefore minimising risk from verification 
bias.46, 90, 93 With the exception of one study,31 all patients were included in the final analysis. 
 
Reference test for osteomyelitis
PCT index test
Patients with suspected bone 
infection
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To help summarise the overall findings from the QUADAS-2 assessment of bias, the following 
interpretations were first applied to the outcomes as recommended.88 A study where a “yes” answer 
was recorded, was judged as low risk of bias, a “no” response was judged as high risk of bias and 
“unclear” judged as unclear risk of bias. For applicability, concerns were simply rated as either “high”, 
“low” or “unclear” risk.  
 
If an individual study was judged as “low” on all the domains relating to bias or applicability, then the 
overall judgement was of low risk of bias or low concern related to applicability for that study. If a 
study however was judged as high risk or unclear risk in only one or more domains then it was judged 
as “at risk of bias” or having “concerns regarding applicability”.88 
 
The results from critical appraisal of bias and applicability for each study are presented in Tables 3a 
and 3b respectively and then summarised in table 4. All studies were considered “at risk of bias” using 
the QUADAS-2 tool. Given the conservative approach for classifying “at risk of bias” using this 
methodology we chose not to exclude any of the eight studies from further statistical analysis but to 
acknowledge any potential limitations we identified in our reporting of outcomes. 
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Table 3b. Critical appraisal applicability 
Citation  
Frist author, date 
publication 
Concerns regarding 









setting of study 
Concerns regarding 
variation in index 
test technology , 
execution or 
interpretation of  
Concerns regarding 
differences in target 
condition specified 
and target condition 
in study 
Caird MS,  
2006 
Low Low Low Low Low Low 
Cui C, 
2017 
Low Low Low Low Low Low 
Eich GF, 
1999 
Low Low Low Low Low Low 
Faesch S, 
2009 
Low Low Low Low Low Low 
Greef E, 
2012 
Low Low Low Low Low Low 
Jung ST, 
2003 
Low Low Low Low Low Low 
Singhal R, 
2011 
Low Low Low Low Low Low 
Sultan J 
2010 
Low Low Low Low Low Low 
 
Low=low concerns regarding applicability
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Table 4. Summary of risk of bias and applicability for QADAS-2 domains 
  Risk of Bias    Applicability 
concerns 
 
First author and 
year 
Patient selection Index test Reference 
standard 
Flow and timing Patient selection Index test Reference 
standard 
Caird MS,  
2006 
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3.4 Review Findings 
 
3.4.1 Diagnostic test measure outcomes from individual studies 
 
The sensitivity and specificity of the index tests for each individual study are included in Table 5. 
Variation in diagnostic accuracy was observed between the two different index tests and within index 
tests across different thresholds. For CRP, the highest sensitivity and specificity recorded from an 
individual study was 100.0 % and 85.9% respectively at a threshold of 20mg/L.92 In comparison for 
PCT, the individual study with the highest sensitivity and specificity recorded was 91.7% and 81.0%, 
at a threshold of 0.2ng/mL.93 The other calculated measures of diagnostic accuracy are also included 
in Table 5 for comparison between index tests. These include positive and negative LR, OR and 
positive and negative predictive values.  
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CRP=C-reactive protein, PCT=procalcitonin, TP=true positive, FP=false positive, TN=true negative, FN=false negative, LR+=positive likelihood ratio,  
LR-= negative likelihood ratio, DOR=diagnostic odds ratio, PPV= positive predictive value, NPP=negative predictive value. 
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3.4.2 Meta-analysis of CRP using index tests with common threshold 
 
Using a bivariate model, meta-analysis was performed for CRP studies with a common threshold of 
20mg/L. The summary point for pooled sensitivity with 95% CI was 0.86 (0.68-0.96) and for specificity 
0.90 (0.83-0.94) (see Figure 5). This corresponds to a positive LR of 8.6 (4.75-15.5) and negative LR 
of 0.15 (0.09-0.25). In all four studies 90-92, 97 however the target condition was septic arthritis. No 
cases of osteomyelitis were included at this threshold level. 
 
 
Figure 5. Forest plots of sensitivity and specificity from studies using a CRP threshold of 20mg/L in 
adolescents and children with septic arthritis. 
 
3.4.3 HSROC curve for CRP combining different positivity thresholds 
 
Hierarchical logistic regression models were used to display estimates of HSROC parameters and 
simple summary measures. The HSROC curve plot best describes how sensitivity and specificity 
trade off at different positivity thresholds values. This was achieved by using only one pair of 
sensitivity and specificity values from each of the four CRP studies at threshold of 20mg/L together 
with one pair each from the two additional studies using CRP threshold of 10 mg/L (see Figure 6).  
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Figure 6. Hierarchical Summary Receiver Operating Characteristic curve for CRP. 
 
3.4.4 Other CRP diagnostic accuracy measures using combined positivity thresholds 
 
Other summary data measures of diagnostic accuracy for CRP included a diagnostic OR (DOR) of 
39.4 (14.85-104.9), positive LR (LR+) 5.3 (2.3-11.9) and negative LR (LR-) 0.1 (0.07-0.2). A pre-test 
versus post-test probability curve for osteoarticular infection using CRP is shown in Figure 7. 
 
 
Figure 7. Line graph of post-test probabilities versus prior probability of osteoarticular infection based 
on positive or negative CRP test result. 
 
3.4.5 Diagnostic accuracy outcomes for PCT 
 
Since only three studies were included for evaluating the diagnostic test accuracy of PCT for 
osteoarticular infection in children and adolescents, it was not possible to a perform meta-analysis in 
STATA to construct either a Forest plot or HSROC curve for PCT. Hence it was also not possible to 
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directly compare the diagnostic accuracy of measurement of CRP with PCT from pooled data using 
these techniques. 
 
In the only paediatric osteoarticular infection study directly comparing the sensitivity and specificity of 
PCT at a threshold of 0.2ng/mL with CRP at a threshold of 10mg/mL93, PCT was shown to be less 
sensitive (91.7% [61.5-99.8] versus 100% [73.5-100.0]) for CPR but more specific (81% for PCT 
[58.1-94.6]) versus 26.3% (9.2-51.2) for CRP.93 From the calculated DOR as a global measure of 
diagnostic accuracy in this study, PCT outperformed CRP, 46.8 (5.51-475.0) to 9.5 (0.5-189.0) 
respectively.93 
 
In the second PCT study that also included both septic arthritis and osteomyelitis cases,31 a test 
threshold of 0.5ng/mL resulted in a sensitivity of 25% (3.2-65.1) and increased specificity of 96.9% 
(94.2-98.6).31 The DOR from this study however, was lower at 10.5 (0.0-53.1). 
 
In the final PCT study using the highest reported threshold for PCT at 3.56 ng/mL in children with 
osteomyelitis only, the specificity was still high at 88.3% (68.9-95.0) and sensitivity 71.4% (41.9-91.6) 
with a DOR of 14.5 (3.4-62.5).95 
 
3.4.6 Heterogeneity  
 
Visual inspection of the Forest plots for CRP (see Figure 2) demonstrated overlapping CIs for both 
sensitivity and specificity and while this does not exclude heterogeneity, it does infer this may not be 
excessive. The distribution of individual studies from the HSROC curve, together with the number of 
studies lying outside the 95% prediction area plus a prediction region that is larger than the 95% CI 
region, all confirm a degree of heterogeneity exists (see Figure 6).  
 
3.4.7 Publication bias 
Deeks’ funnel plot for examining publication bias for meta-analysis of diagnostic test accuracy studies 








This systematic review has identified eight studies from a total of 3,086 that include the measurement 
of serum CRP and or PCT in children and adolescents presenting to hospital with suspected bone 
and joint infection. The results from these analyses confirm the summary point pooled estimates of 
both sensitivity and specificity when using a CRP threshold of 20mg/L as a diagnostic test. We have 
also provided additional statistical precision of test accuracy when combining test thresholds for both 
10mg/L and 20mg/L for CRP using HSROC modelling. This included a diagnostic OR (DOR) of 39.4 
(14.85-104.9), positive LR (LR+) 5.3 (2.3-11.9) and negative LR (LR-) 0.1 (0.07-0.2). At the time of 
performing this review, there was insufficient data to perform a meta-analysis for PCT. Formal critical 
appraisal highlighted the potential for “at risk of bias” in those studies included in statistical analysis. 
This review presents new quantitative data on the diagnostic accuracy of CRP for both bone and joint 















4 Discussion and conclusion 
4.1 Introduction 
 
This chapter explores and explains the major findings from this review in the context of the existing 
body of knowledge in this area. It also considers the limitations of this review and discusses the 
implications of the results for future clinical practice and research.  
 
4.2 Research objective 
 
The objective of this systematic review was to identify, evaluate, extract and synthesise the best 
available scientific evidence for the diagnostic test accuracy of serum measurement of PCT compared 
to CRP in children and adolescents aged between one month and 18 years of age, admitted to 
hospital with suspected osteoarticular infection.  
 
The findings from this review support the use of CRP as a preferred biomarker over PCT in this 
setting. Based on the currently available data, there is insufficient evidence to recommend that serum 
measurement of PCT can be used as either an additional or replacement test for the routine 
evaluation of suspected bone and joint infection in children and adolescents. 
 
4.3 Systematic review findings in the context of existing results 
 
4.3.1 The diagnostic test performance of CRP using a common test threshold of 20mg/L in children 
and adolescents with suspected septic arthritis 
 
This review has provided the first summary operating point estimates for CRP exclusively in children 
and adolescents with suspected septic arthritis. Using a bivariate model, the pooled sensitivity with 
95%CI for CRP at a common diagnostic threshold of 20mg/L was shown to be 0.86 (0.68-0.96) and 
specificity 0.9 (0.83-0.94). From the systematic literature search performed in this review, no other 
meta-analysis was identified when confined to the paediatric age group with this condition.  
 
In a recent meta-analysis where researchers did combine both adult and paediatric patients with 
septic arthritis, to evaluate both PCT and CRP as diagnostic markers, the pooled sensitivity and 
specificity reported for CRP were both significantly lower at 0.45 (0.35-0.55) and 0.07 (0.02-0.25) 
respectively. 12 The analysis for the CRP index test included five adult and one paediatric study only 
and included CRP thresholds ranging from 18-50 mg/L. Estimating sensitivity and specificity by 
pooling studies which mix thresholds however will produce an estimate that relates to some notional 
unspecified average of thresholds and this may be clinically unhelpful.98 
 
The positive and negative LRs provided in this systematic review were calculated from the summary 
point estimates for both sensitivity and specificity using the common 20mg/L threshold. Likelihood 
ratios provide health care practitioners with more clinically meaningful information at an individual 
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patient level. When evaluating the post-test probability for joint infection in the paediatric setting alone, 
the positive LR of 8.6 as reported indicates that a patient with a positive test result has more than 8.6 
times the odds of having septic arthritis. The negative LR of 0.15 indicates a patient with a negative 
test result has 15 times less the odds of having the disease.  
 
When comparing the LRs calculated from this review in children and adolescents with the pooled 
adult and paediatric data combined for CRP for septic arthritis only, the LRs are surprisingly 
inconsistent. The combined study resulted in an LR+ of 0.4 and LR- of 6.79.12 In practical terms an LR 
+ less than 1.0 means that a positive test result for CRP is less likely to occur in patients with septic 
arthritis than without the infection while an LR- greater than 1.0 means that a negative CRP test is 
more likely to occur in people with the septic arthritis than without. Clearly with such poor test 
accuracy performance, measuring serum CRP in this setting would offer no advantage to either 
patient or clinician.  
 
The cause for such a wide discrepancy in the diagnostic accuracy performance is likely to be multi-
factorial. While the sensitivity and specificity of a diagnostic test varies as the positivity thresholds 
change, other important factors may contribute to the variation observed. 99 As diagnostic test 
accuracy outcome measures are not fixed properties of the test, variables including patient groups, 
spectrum of disease, clinical setting and test interpreters can significantly affect sensitivity and 
specificity outcomes.100 
 
Assumptions that children and adults can be combined in a meta-analysis to determine summary 
point estimates of sensitivity and specificity may be inappropriate from a biological plausibility 
perspective. Evidence from another earlier published systematic review evaluating the diagnostic 
accuracy of CRP in adults with septic arthritis clearly demonstrated consistently lower specificity 
values when compared to the paediatric literature.101 Differences in the disease presentation, 
pathogens responsible for infection, pathophysiology, immune response to infection, and kinetics of 
CRP include just some of the reasons why combining these two populations into a single summary 
measurement could be problematic. The published systematic review for septic arthritis did not 
perform subgroup analysis for CRP by population type to confirm this as a significant source of 
heterogeneity.12 The methodological concerns raised with this systematic review may have also 
contributed towards the variation in test accuracy outcomes observed.84  
 
In summary the diagnostic accuracy of CRP was observed to be higher in the paediatric setting for 
acute septic arthritis in this review compared with the published data that combined both adults and 
children. The size of this effect we observed from this review and meta-analysis appears to be 
significant without any overlap in the 95% CIs and while “risk of bias” existed in the quality of the 
evidence used, there were low concerns regarding the applicability of this evidence. 
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4.3.2 The diagnostic accuracy performance of CRP across positive thresholds in children and 
adolescents with either bone and/or joint infection 
 
To determine the summary test performance of serum measurement of CRP across all osteoarticular 
infections in children and adolescents it was necessary to combine the data from different test 
thresholds and include both bone and joint infections as the target condition. Using a hierarchical 
logistic regression model analysis it was possible to generate an HSROC curve for CRP (to show the 
trade-off of sensitivity and specificity), estimate global measures of diagnostic accuracy for CRP such 
as DOR and provide overall summary estimates of LRs to improve clinical interpretation.   
 
From this meta-analysis the DOR for the overall test performance of CRP in children and adolescents 
with osteoarticular infection was 39.4 (14.8-104.9). When comparing these data to the only other 
systematic review and meta-analysis using combined adult and children and including both bone and 
joint infection, the DOR for CRP was reported to be lower at 3.5 (1.3-9.7).11 While a wide confidence 
interval was observed in the paediatric only data, there was no overlap in CIs between these two 
cohorts and the greater than ten-fold difference in the global test accuracy of CRP was noted.  
 
When evaluating the likelihood ratios from this review for overall test performance of CRP for both 
bone and joint infection, the LR+ was 5.3 (2.3-11.9) and LR- 0.1 (0.07-0.2). This compares favorably 
with the published finding from the combined adult and paediatric CRP data with a reported LR+ of 
1.39 (1.17-1.65) and LR- of 0.4 (0.12-1.36).11 
 
Again, differences in the diagnostic test outcome measures between the population cohorts were 
observed. The same rationale for the differences observed in sensitivity and specificity of CRP 
between paediatric only versus adult and paediatric data for septic arthritis as the target condition also 
applies to the variations observed using the DOR and LRs when combining both bone and joint 
infections together as the target condition.  
 
The results from this systematic review and meta-analysis suggest measurement of CRP may 
perform better when suspecting osteoarticular infections in children and adolescent patients 
compared with adults. Recommendations for the use of CRP in children and adolescents based on 
outcomes from combining adult and paediatric data may therefore be inappropriate and misleading. 
Future evaluations of test accuracy outcome measures for CRP in osteoarticular infections should 
always include separate analysis of children and adolescents from adults. 
 
In summary by combining only paediatric data for CRP, we observed an improvement in the 
diagnostic test accuracy for this biomarker in both bone and joint infection in children and adolescents 
compared to the test performance outcomes when combining all age groups. This effect was most 
obvious with the LR test outcomes. 
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4.3.3 The diagnostic test accuracy performance of PCT in children and adolescents in bone and 
joint infections. 
 
The diagnostic test outcome measures for PCT in this setting are based on a limited number of 
studies. This review performed a broader search strategy than both of the previous published 
systematic reviews combining adults and children.11, 12 While identifying more PCT diagnostic test 
accuracy studies using the search strategy described in this review, in total only three paediatric 
studies satisfied all the inclusion and methodological criteria for subsequent evaluation and analysis. 
31, 93 95 There was only one study that was included in both the previously published systematic 
reviews and this review. 31  
 
A comparative evaluation of the test performance of PCT in this setting was the primary objective of 
this review. A meta-analysis using the PCT studies however was not feasible due to the low number 
of studies. As per protocol, this was replaced by narrative summary of the diagnostic test outcomes 
for PCT.  
 
From the summary results (Table 5), variability across all key test performance outcomes for PCT, 
was found. The range observed for sensitivity was wide, (25.0% to 91.7%), but narrower for specificity 
(71.4% to 96.9%). The positive LRs were also widely spread from 2.9 to 8.0 with LR- tighter in range 
(0.1 to 0.2). Finally, the DOR variability observed across all three PCT studies was from 10.5 to 46.8. 
The most important explanation for this observed variability across studies is the different test 
threshold levels employed for PCT. The threshold levels were also widespread including values of 
0.2ng/L, 0.5ng/L and 3.56ng/L. The study reporting the highest sensitivity (91.7%), specificity (81.0%) 
and DOR (46.8) occurred at the lower test cut off for PCT at 0.2ng/L.93  
 
This review excluded a paediatric study that was included in both of the other systematic reviews 
comparing PCT and CRP in children and adults with osteoarticular infections. 30 The reason for 
exclusion from this review was that neonates and adolescents up to 19-years of age were part of the 
analysis and this was outside the age range in the published protocol. With this limitation in mind, the 
sensitivity and specificity reported from this study using a cut off of 0.50ng/L for PCT was 43.5% and 
100% respectively and most consistent with the included study in this review also using the same cut-
off.30, 31  Again this demonstrates the importance of the threshold effect on the diagnostic test 
accuracy outcome measures.  
 
Interestingly, published meta-analyses performed to evaluate the diagnostic test accuracy of PCT in 
other disease settings such as sepsis more often differentiate adults from the paediatric age and 
within paediatrics further separate neonates from other cohorts.102 103, 104 Clearly other investigators 
recognise the potential for age to be a significant potential confounder in the assessment of PCT test 
outcomes. This further supports the premise that using combined age population data for inference 
across all age cohorts may has limitations.  
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In summary there appears to be variability across the test performance measurements for PCT in the 
paediatric setting when used as a diagnostic test for suspecting osteoarticular infection.  
 
4.3.4 Comparing the diagnostic test accuracy performance of PCT and CRP 
 
The test performance results where diagnostic index tests are compared indirectly between patients 
may differ to those in which all patients receive all tests and the reference test. The direct comparative 
design however is the preferred methodology to help guide clinicians in their test selection and this 
approach should be routinely undertaken whenever possible.105 
 
In the only direct comparison study included in this review, PCT (at a threshold of 0.2 ng/mL) was 
reported to be more specific, (0.81 [0.58-0.95]) than CRP at a threshold of 10 mg/L, (0.26 [0.92-0.51] 
for children presenting to hospital with suspected acute septic arthritis and osteomyelitis.93 Sensitivity 
however was higher for CRP at 1.00 (0.73-1.00) versus 0.92 (0.61-0.99) for PCT.93 The small number 
of enrolled cases (n=33) was a limitation of this study.93 In the only other direct comparative published 
study identified in children and adolescents with acute osteoarticular infection, PCT again 
demonstrated higher specificity (100%) compared to CRP (19%) but again with lower sensitivity 43.4 
versus 78.2 respectively.30 This study was excluded as it included both neonates and adults up to 19 
years of age. 
 
In both of the combined adult and paediatric meta-analyses performed, the specificity of PCT was 
also noted to be higher than for CRP, but the data using direct comparisons were incomplete for both 
these studies.11, 12 In the meta-analysis examining septic arthritis cases only, a total of six of the 10 
studies analysed included both index tests with the reference test in the same patient.12 In the second 
review of both bone and joint infections, only three of the included seven studies incorporated both 
index tests and reference tests for each patient.11 Even with this constraint, there remains consistent 
evidence across all studies to suggest higher a specificity can be expected when measuring serum 
PCT compared to serum CRP as a diagnostic test for children and adolescents with presumed 
osteoarticular infection.  
 
The published combined adult and paediatric meta-analyses for PCT and CRP also performed 
subgroup analysis after removal of one paediatric study in the first study and two in the second 
study.11, 12 In both cases the re-analyses did not appear to significantly change any of the diagnostic 
accuracy parameters examined given significant overlap was still observed with the wide confidence 
intervals. 
 
In summary, given the limited direct and indirect comparative data between CRP and PCT from this 
systematic review and the wide variability in results observed with serum measurement of PCT, it was 
not possible to provide an accurate assessment of the diagnostic test performance of PCT in children 
and adolescents presenting to hospital with osteoarticular infection.  
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4.4 Unexpected findings 
 
The most unexpected finding from this review was the number of diagnostic test accuracy studies that 
did not directly compare the two index tests (CRP and PCT) to the reference test in the same patient. 
This was also observed in many of the studies not meeting the inclusion criteria for this review. This 
finding however is not limited to the paediatric setting and is shown to be consistent across the 
published diagnostic test accuracy literature.106 Improved guidance on both methodology and 
reporting will assist to improve the quality of these studies.  
 
4.5 Strengths of this review 
 
The value of any systematic review depends upon the quality quantity, homogeneity of the included 
studies but equally important the rigor of the methodology adopted in both of the systematic review 
and included studies.73 This review followed the preferred reporting items for systematic reviews and 
meta-analysis of diagnostic test accuracy studies using the PRISMA-DTA, 27 step check list first 
published in 2009.107 Significantly this review was conducted without any deviation from the published 
protocol.1  
 
The review question was of high clinical importance. Given the uncertainty surrounding the diagnostic 
accuracy of PCT in children and adolescents with suspected osteoarticular infection and the financial 
burden to our health system in performing a more expensive alternative test, more evidence was 
needed to guide clinicians. Importantly the inclusion criteria in this review were carefully defined to 
focus on the paediatric setting not specifically addressed in previous systematic reviews. 11, 12 
 
While evidence is emerging to support more efficient search strategies for systematic reviews of 
diagnostic test accuracy by limiting searches to data bases such as MEDLINE (PubMed) and Embase 
(Ovid) a more comprehensive search was used for this review as described in our methods.108 To 
allow replication of our methodology, full search strategies are included in Appendix 1. In the 
previously published systematic reviews no more than three data bases were searched for each 
review, resulting in 68 citations in one review and 205 in another before undertaking screening.11, 12 In 
comparison this review included four data bases, unpublished and grey literature and started with 
over 900 citations after duplicates were removed. This review also avoided the use of methodological 
filters shown to miss relevant diagnostic test accuracy studies.109 The overall aim of this more 
extensive search was to identify as many relevant paediatric studies as feasible and to help mitigate 
publication bias.  
 
Another strength of this review was the use of two independent reviewers to critically appraise each 
study for methodological quality by applying the QUADAS-2 critical appraisal tool for diagnostic test 
accuracy.88 This tool aims to improve transparency in the assessment of bias. 
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It was not always clear under what circumstances the variations seen with the different 
methodological designs may change the estimates of diagnostic accuracy performance. This 
uncertainty particularly applies to diagnostic case-control studies, where it has been shown that bias 
may lead to a two or three fold higher estimate of diagnostic accuracy compared to cohort selection 
studies.110 In this review, seven of the eight included studies used a cohort study design further 
minimising this risk of bias. 
 
4.6 Limitations of this review 
 
Several limitations were identified with this systematic review and meta-analysis. Only studies in 
English language were included in this review. A systematic review of English language restriction on 
systematic review based meta-analyses however found overall no evidence of bias from language 
restriction in conventional medicine.111, 112 
 
While one of the strengths of this review was the inclusion of studies using a consecutive cohort-cross 
sectional design, the critical appraisal identified some potential risks of bias. The most common and 
consistent potential source of bias identified included interpretation related bias. Insufficient 
information was a systematic and significant finding across many of the studies and contributed to 
having to document an unclear answer to many of the appraisal questions. Less common sources of 
bias included failure to pre-specify the test threshold in half of the studies and a degree of 
inconsistency from not all patients not receiving the same reference test. The extent from the impact 
of this on the overall statistical findings however is considered to be low given that the index tests are 
usually performed and reported independently and that the reference test includes objective criteria 
measures. 
 
In the absence of any sample size calculations of individual studies it is difficult to comment on 
whether any of the included studies were powered adequately. 
 
It was not feasible to perform subgroup analyses to statistically identify differences in the diagnostic 
test performance of either CRP or PCT based on the primary site of infection, either bone or joint. 
While this would be interestingly academically from a clinical perspective it is less important given 
differentiating the two conditions is not always possible and both conditions can occur simultaneously. 
 
As with the other published meta-analyses on this topic, the meta-analyses in this review were also 
performed using a small number of studies (n= 4-6) with sample sizes ranging from 33 to 339. It is 
well recognised that small numbers of both may contribute to sampling and statistical error resulting in 
both low precision and low confidence in the estimated effects observed.113 
 
While heterogeneity is anticipated in diagnostic test accuracy reviews, using methods such as 
Cochrane Q or I2 statistics may not be informative as they do not account for heterogeneity due to 
threshold effects.99 Instead this review relied on graphical visualisation from the CIs with Forest plots 
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and prediction regions from the HSROC curve. Using this approach, it was not possible to accurately 
quantify the degree of heterogeneity where it exists. 
 
In this review it was not possible to evaluate the test accuracy performance of the PCT in children and 
adolescents using statistical methods. A commentary and overview were therefore provided on the 
three studies included. This summary is subjective with the same limitations of a narrative review. 
 
The risk from publication bias in this meta-analysis of diagnostic test accuracy was evaluated as 
recommended using Deeks’ funnel plot for asymmetry.114 While this test was not significant, it is 
underpowered when using a small number of studies (as was the case here) and may have been 
falsely reassuring.115 
 
The GRADE guidelines use a structured framework for evaluating certainty across a body of evidence 
and provide readers with a level of confidence in the effect estimates observed.116 This review 
included a combination of both meta-analysis and narrative summary to evaluate the test accuracy 
performance which proved challenging to incorporate into the current GRADE appraisal format. It has 
been acknowledged however that further development is still required before it can be widely applied 
to all systematic reviews of test accuracy.117 
 
4.7 Implications for clinical practice 
 
The results from this study provide clinicians with increased statistical precision regarding the 
diagnostic test performance of CRP in children and adolescents with suspected acute bone and joint 
infection. It is recommended that CRP remain the preferred biomarker to help define the post-test 
probability of suspected acute osteoarticular infection (Grade A, JBI grade of recommendation: a 
strong recommendation for a certain health management strategy where (1) it is clear that desirable 
effects outweigh undesirable effects of the strategy; (2) where there is evidence of adequate quality 
supporting its use; (3) there is a benefit or on impact on resource use, and (4) values, preferences 
and the patient experience have been taken into account.).  
 
Due to the limited evidence available, no recommendation can be made regarding the use of PCT as 
either and adjunct or replacement test in the paediatric setting; further research is required (Grade A, 
JBI Grade of Recommendation). Clinicians should be cautious when requesting and or 
recommending PCT routinely in isolation for children and adolescents with suspected acute bone and 
joint infection, until it is possible to make a better informed decision regarding the diagnostic accuracy 
of this test in this population.  
 
While the results from predominately adult-based systematic reviews may be illuminating for clinicians 
working in paediatrics, this information alone must not form the basis on which decisions should be 
made regarding children and adolescents. Based on the findings and recommendations from this 
review it is suggested that local, national and international clinical guidelines continue to recommend 
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measurement of serum CRP in their diagnostic evaluation of bone and joint infection in children and 
clinicians should await further evidence before consideration is given to the role of PCT. These 
recommendations are consistent with the core aims of the Choosing Wisely campaign of promoting 
only those investigations that are evidence based.  
 
The publication of the systematic review protocol and the systematic review should help provide 
clinicians and researchers with access to new scientific information specifically for the paediatric 
setting. Hopefully this will generate ongoing clinical debate and further recommendations regarding 
the existing use and/or future use of PCT in children and adolescents presenting to hospital with bone 
and joint infection in their own health care setting. 
 
4.8 Implications for research 
 
The research process for this systematic review and the results obtained from the meta-analysis have 
identified several important gaps in the knowledge base that may have important implications for the 
direction of future research in this area. These are discussed below. 
 
4.8.1 The next step 
 
The most expedient and least resource demanding response to address the research questions left 
unanswered would be to first extend the original age inclusion criteria in the published protocol so that 
19-year-old patients and neonates would be eligible. This step would increase the number of included 
studies potentially making meta-analyses for PCT studies more feasible, but with this approach 
comes additional limitations (see below section 4.8.2). The added advantage of this approach is that it 
may also allow subgroup analysis by different age groups. If this step was unsuccessful however, it 
would be reasonable to wait for more publications before updating this systematic review. Although 
this approach may capture newer studies it would also delay any further formal recommendations and 
may not improve the methodologically quality of included test diagnostic accuracy studies. 
Improvements in the quality of studies would require a direct comparative consecutive cohort cross 
sectional study design including both index tests simultaneously with a reference test. Ideally this 
would be prospective and across a defined age group. A sample size calculation would be essential 
to ensure adequate power to detect the anticipated effect was reached. In reality all of these 
approaches may be required to make the best evidence-based recommendations regarding the 
diagnostic accuracy of PCT in children and adolescents with acute osteoarticular disease. This review 
provides the foundation on which to build these additional layers. 
 
4.8.2 PRISMA-C, PRISMA-PC and PRISMA-DTA 
 
Given the large degree of physiological, pharmacological, and psychological differences among 
different age groups (e.g. neonates, children, adolescents, adults, elderly people), it is important that 
research questions be age-specific and that evidence be reported in such a way that the resulting 
recommendations are appropriate for each age group.118 Furthermore child health systematic reviews 
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and meta-analyses exhibit incomplete reporting of child-centric topics. Reports and protocols with a 
mixed children/adult population are more prone to incomplete reporting than child-only populations.118 
To overcome these limitations and address some of the more child specific features, PRISMA-C for 
children and the PRISMA-PC protocol for children are being developed.119 These will be welcomed for 
paediatric researchers but careful consideration and clear guidance will be needed to harmonise the 
paediatric specific methodology with the newly updated PRISMA-DTA guidelines released in August 
2020.120 As the PRISMA framework forms the preferred methodology for systematic reviews and 
meta-analyses, there is a greater sense of urgency for completion of the paediatric guidelines and to 
provide the necessary direction and support for researchers working in the paediatric diagnostic test 
accuracy field. 
 
4.8.3 Sample sizes and power analysis 
 
None of the individual diagnostic accuracy studies included in this review performed a sample size 
calculation. This is an important consideration before conducting a diagnostic study to justify the 
results, conclusions and recommendations. This helps ensure that the results obtained from the 
subsequent analysis will provide the test with a desired minimum value for both sensitivity and 
specificity together with a sufficient level of power to detect and effect and low level of type 1 error.121 
In a published study conducted to evaluate the impact of study size on meta-analyses, the authors 
found that when at least two adequately powered studies were included, the underpowered studies 
often contributed little additional information. However they found that underpowered studies made up 
the entirety of the evidence in most Cochrane reviews.122 Researches wishing to perform rapid 
reviews however may benefit from this knowledge when seeking to reduce costs and time. Sample 
size assessment should therefore be considered in future methodological critical appraisal tools of 
diagnostic test accuracy studies. 
 
One of the most powerful and persuasive reasons for performing meta-analyses is the desire to 
increase the statistical power to detect an effect when one exists. In meta-analyses which lack power, 
precision in estimation is also lacking, and therefore the summary effect is imprecisely estimated.123 If 
meta-analyses are performed too early, before enough studies are available, there is potential risk 
from erroneous summary statistics and incorrect conclusions. More dialogue with statisticians would 
be welcomed in exploring the application of power analysis for systematic reviews with meta-analysis 
in diagnostic test accuracy studies into the future. 
 
4.8.4 Hypothesis testing and study design 
 
Most randomised controlled trials pre-specify a test hypothesis that the intervention under evaluation 
improves outcomes which is statistically tested against a null hypothesis that has no effect. The 
sample size is calculated and a test statistic with corresponding p-value determined.124 The situation 
for individual diagnostic test accuracy studies however is very different. According to one study only, 
12% reported any statistical test of a hypothesis related to the study objectives and no more than 11% 
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reported a sample size justification.125 Having a clear and pre-specified hypothesis: 1) forces 
researchers to express minimally acceptable criteria for accuracy values (e.g. sensitivity and 
specificity) that would make the test clinically fit for purpose before initiating the study, 2) enables 
informed judgement of the appropriateness of the study design, sample size, statistical analysis and 
conclusions, and 3) may minimise the risk from over-interpretation of findings.124 The same 
hypothesis driven approach should also be applied and documented in protocols for meta-analyses of 
diagnostic test accuracy. 
 
Critical appraisal of the methodological quality of diagnostic test accuracy studies includes 
assessment and evaluation of the study design.88 Clear and consistent distinction of the different 
study designs is important for diagnostic test accuracy studies to ascertain the risk of bias.126 
Unfortunately test accuracy studies are often unclearly labelled in the medical literature or not defined 
at all, making assessment more difficult and leaving the reader to make a conclusion.126 Fortunately 
an algorithm for the classification of test accuracy studies in systematic reviews has been proposed to 
improve consistent classification of study designs and this could be incorporated into the handbooks 
and guidelines for systematic review researchers in this field.126 Making explicit statements regarding 
the study design in individual diagnostic test accuracy studies as recommended in the Standards for 
Reporting of Diagnostic Accuracy Studies (STARD) should be a mandatory requirement.127 Efforts are 
currently underway to extend the QUADAS-2 tool for assessment of methodological quality of 
diagnostic tests with incorporation of the new comparative QUADAS-C tool.128 
 
Where new diagnostic tests are being evaluated as either a replacement or additional test, direct 
comparison of the new index test with the existing best practice or routine test should be the preferred 
methodology, as this approach provides the most robust comparison with less risk of bias.129, 130 In 
this systematic review only one study included direct comparison of CRP with PCT. Where this direct 
approach is not feasible then the use of network meta-analysis may provide an alternative option, but 
this requires researchers including statisticians to become familiar with this more complex test 
methodology. Few published articles were identified using network meta-analysis specifically for 
diagnostic test accuracy studies when exploring this option for this systematic review. Clearly this is 
an emerging field, but more detailed guidance for researchers with unambiguous examples would be 
welcomed. 
 
4.8.5 Rapid reviews for diagnostic test accuracy studies 
 
Considerable time and resources were directed to following the comprehensive search strategy 
methodology for this systematic review. Streamlining this procedure by using a rapid review process 
for searching and synthesis of information offers researchers an attractive and pragmatic option.131 
This could also improve upon the turnaround time when more rapid laboratory information is required. 
Half of Cochrane reviews were published later than the stated aim of two years.132 Using limited or 
accelerated methods that have been validated for diagnostic test accuracy studies to expediate the 
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time and to obtain a comparable outcome would appear to be a significant advantage. This work is 
currently under way and researchers need to be aware of such advances.131 
 
4.8.6 Assessing heterogeneity in diagnostic test accuracy studies  
 
The assessment, measurement, interpretation and presentation of heterogeneity in meta-analysis of 
diagnostic test accuracy remains complex and challenging. Relying on subjective visual assessment 
to identify statistical heterogeneity is not uncommon but does not allow the extent of heterogeneity to 
be accurately assessed. There is general acknowledgement of the level of difficulty in identifying and 
measuring the degree of heterogeneity and the ways this is handled.133 While these reviews should 
be carried out with a statistician familiar with this field, substantial education and training to assist 
researchers in performing these tasks is needed. 
 
4.8.7 Closer research collaboration  
 
Closer collaboration with paediatric clinicians, medical laboratory scientists and researchers for 
diagnostic test accuracy studies could improve the quality of published systematic reviews and meta-
analyses. Topic content expertise is critical to ensuring clinical relevance within an appropriate 
setting, but this must be carefully balanced with systematic review expertise to provide the best 
available scientific evidence. Meta-analyses for diagnostic tests accuracy should always have 
available a specialist statistician to guide researchers. 
 
4.9 Conclusion  
 
This systematic review with meta-analyses provides clinicians and researchers with new evidence 
related to the test accuracy performance of CRP in children and adolescents with suspected 
osteoarticular infection. 
 
We identified an insufficient number of scientific studies from our inclusion criteria to perform a meta-
analysis of the test accuracy of PCT and compare this statistically with CRP. While other authors 
have achieved this by combining adult, child and adolescent data, we have demonstrated the 
potential limitations of transferring predominately adult outcomes to paediatric patients. Clinicians 
should remain vigilant to the indiscriminate creep of PCT use into routine practice without a clear 
understanding of the test accuracy performance in the paediatric setting.  
 
Ideally, further studies using direct comparisons of CRP and PCT with a single reference standard in 
children and adolescents will be conducted. Future diagnostic test accuracy studies and systematic 
reviews should include a pre-specified hypothesis that can be statistically tested against a null 
hypothesis using sample size calculations when formally evaluating these index tests.  
 
This review will permit researchers to update the meta-analysis for CRP and PCT in this setting by 
either adjusting inclusion criteria and or awaiting new publications. This research will hopefully 
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facilitate the next step using meta-analyses to compare the diagnostic test accuracy of CRP and PCT 







































5.1 Appendix 1 
 
5.1.1 The full search strategy for EMBASE (Ovid) and Cochrane centre of controlled trials (Ovid) 
is included below. All final searches were performed on the 30th July 2019. 
 
#1 exp Osteomyelitis 
#2 Arthritis, Infectious/ 
#3 Osteomyelitis.ti,ab,kw. 
#4 ((osteoarticular or bone* or joint*) adj4 infect*).ti,ab,kw. 
#5 (arthritis adj2 (septic or sepsis or infectious or bacterial)).ti,ab,kw. 
#6 or/1-5 
#7 Procalcitonin/ 
#8 (pro?calcitonin or PCT).ti,ab,kw. 
#9 C-reactive protein/ 
#10 (C-reactive protein or CRP).ti,ab,kw. 
#11 or/7-10 
#12 Infant/ or exp Child/ or Adolescent/ or Paediatrics/ 
#13 (infant* or child* or adolescent* or juvenile*or p?ediatric* or girl* or boy*).af. 
#14 12 or 13 
#15 6 and 11 and 14 
#16 15 not Animals/ not (Animals/ and Human/) 
 
5.1.2 The full search strategy for MEDLINE (PubMed) is included below: 
 
((((((((((((osteomyelitis[MeSH Terms]) OR (osteomyelitis AND infection[MeSH Terms])) OR arthritis, 
infectious[MeSH Terms]) OR osteomyelitis[Title/Abstract]) OR (osteoarticular infection*[Title/Abstract] 
OR bone infection*[Title/Abstract] OR joint infection*[Title/Abstract])) OR (septic arthritis[Title/Abstract] 
OR infectious arthritis[Title/Abstract] OR bacterial arthritis[Title/Abstract]))) AND 
((((procalcitonin[MeSH Terms]) OR (procalcitonin[Title/Abstract] OR PCT[Title/Abstract])) OR C-
reactive protein[MeSH Terms]) OR (C-reactive protein[Title/Abstract] OR CRP[Title/Abstract]))) AND 
(((Infant or child or adolescent or pediatrics[MeSH Terms])) OR (infant*[Title/Abstract] OR 
child*[Title/Abstract] OR adolescent*[Title/Abstract] OR pediatric*[Title/Abstract] OR 
paediatric*[Title/Abstract])))) NOT ((animals[MeSH Terms]) NOT humans[MeSH Terms]))) 
 
5.1.3 The full search strategy for Web of Science is included below: 
 
TS=(osteomyelitis OR "septic arthritis" OR "infectious arthritis" OR "bacterial arthritis" OR "bone 
infection*" OR "joint infection*"OR "osteoarticular infection*") AND TS=(“c-reactive protein” OR CRP 




5.1.4 The full search strategy for Mednar : 
 
(osteomyelitis OR “septic arthritis” OR “osteoarticular infection” OR “bone infection” OR “joint 
infection” OR “infectious arthritis” OR “bacterial arthritis” ) AND (“C-reactive protein” OR CRP OR 
procalcitonin OR PCT) AND (Infant* OR child* OR adolescent* OR p?ediatric) 
  
5.1.5 The full search strategy for Open Grey: 
osteomyelitis OR “septic arthritis” OR “osteoarticular infection” OR “bone infection” OR “joint infection” 
OR “infectious arthritis” OR “bacterial arthritis” AND “C-reactive protein” OR CRP OR procalcitonin 
OR PCT AND Infant* OR child* OR adolescent* OR paediatric* OR pediatric* 
 
5.1.6 The search strategy for ProQuest dissertations and theses: 
 
AB,TI(osteomyelitis OR “septic arthritis” OR “osteoarticular infection” OR “infectious arthritis” OR 
“bone infection” OR “joint infection” OR “bacterial arthritis”) AND AB,TI(infant* OR child* OR p?diatric* 
OR adolescent*)  
 
5.1.7 The search strategy for Google scholar: 
 
osteomyelitis OR “septic arthritis” OR “osteoarticular infection” OR “bone infection” OR “joint infection” 
OR “infectious arthritis” OR “bacterial arthritis” AND “C-reactive protein” OR CRP OR procalcitonin 
OR PCT AND Infant* OR child* OR adolescent* OR paediatric* OR pediatric 
 
5.2 Appendix 2 
 
Bibliography of excluded references and reasons: 
 
1. Aigner RM, Fueger GF and Vejda M. Follow-up of osteomyelitis of infants with systemic serum 
parameters and bone scintigraphy. Nuklearmedizin 1996; 35(4): 116-121.  
Reason for exclusion: No CRP cut off in article and no raw data included in analysis. 
 
2. Akinkugbe O, Stewart C and McKenna C. Presentation and Investigation of Pediatric Bone and 
Joint Infections in the Pediatric Emergency Department. Pediatr Emerg Care 2018.  
Reason for exclusion: No criteria included for the diagnosis of osteoarticular disease. No defined case 
definition. 
 
3. Arnold JC, Cannavino CR, Ross MK, Westley B, Miller TC, Riffenburgh RH, et al. Acute bacterial 
osteoarticular infections: eight-year analysis of C-reactive protein for oral step-down therapy. 
Pediatrics 2012; 130(4): e821-828.  
Reason for exclusion: CRP for oral stepdown and not a diagnostic paper. 
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4. Aupiais C, Basmaci R, Ilharreborde B, Blachier A, Desmarest M, Job-Deslandre C, et al. Arthritis in 
children: comparison of clinical and biological characteristics of septic arthritis and juvenile idiopathic 
arthritis. Arch Dis Child 2017; 102(4): 316-322.  
Reason for exclusion: This study does not allow for extraction or calculation of any of the parameters 
to determine diagnostic test accuracy. 
 
5. Bacon MA, Bailie HC and Stohr KK. Kocher's Criteria: Is it always useful? Archives of Disease in 
Childhood 2016; 101 (Supplement 1): A36-A37.  
Reason for exclusion: No CRP raw data included and no definition of acute osteoaricular infection 
included. 
 
6. Baker AD and Macnicol MF. Haematogenous osteomyelitis in children: epidemiology, classification, 
aetiology and treatment. Paediatrics and Child Health 2008; 18(2): 75-84. 
Reason for exclusion: Review article only, no raw data included in this paper. 
 
7. Barriocanal MB, Jimenez MR, Amador JTR, Insuga VS, Sanchez AB and Jareno MLL. Acute 
osteomyelitis: epidemiology, clinical manifestations, diagnosis and treatment. Anales De Pediatria 
2013; 78(6): 367-373. 
Reason for exclusion: Article written in Spanish. 
  
8. Basmaci R, Ilharreborde B, Bonacorsi S, Kahil M, Mallet C, Aupiais C, et al. Septic arthritis in 
children with normal initial C-reactive protein: Clinical and biological features. Archives De Pediatrie 
2014; 21(11): 1195-1199. 
Reason for exclusion: Article written in French. 
 
9. Benvenuti MA, An TJ, Mignemi ME, Martus JE, Mencio GA, Lovejoy SA, et al. A Clinical Prediction 
Algorithm to Stratify Pediatric Musculoskeletal Infection by Severity. Journal of Pediatric Orthopaedics 
2019; 39(3): 153-157. 
Reason for exclusion: This paper includes soft tissue infections and does not discriminate between 
bone and joint and soft tissue infections. 
 
10. Bonhoeffer J, Haeberle B, Schaad UB and Heininger U. Diagnosis of acute haematogenous 
osteomyelitis and septic arthritis: 20 years experience at the University Children's Hospital Basel. 
Swiss medical weekly 2001; 131(39-40): 575-581. 
Reason for exclusion: Criteria for reference test are insufficient. 
  
11. Brown MD. Test characteristics of C-reactive protein (CRP) for pediatric septic arthritis. Journal of 
pediatric orthopedics 2004; 24(3): 344.  
Reason for exclusion: Letter to editor. 
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12. Bueno Barriocanal M, Ruiz Jimenez M, Ramos Amador JT, Soto Insuga V, Bueno Sanchez A and 
Lorente Jareno ML. Acute osteomyelitis: Epidemiology, clinical manifestations, diagnosis and 
treatment. Anales de Pediatria 2013; 78(6): 367-373. 
Reason for exclusion: Article written in Spanish. 
 
13. Butbul-Aviel Y, Koren A, Halevy R and Sakran W. Procalcitonin as a diagnostic aid in 
osteomyelitis and septic arthritis. Pediatr Emerg Care 2005; 21(12): 828-832.  
Reason for exclusion: Age group does not meet inclusion criteria. 
 
14. Calvo C, Nunez E, Camacho M, Clemente D, Fernandez-Cooke E, Alcobendas R, et al. 
Epidemiology and management of acute, uncomplicated septic arthritis and osteomyelitis spanish 
multicenter study. Pediatric Infectious Disease Journal 2016; 35(12): 1288-1293.  
Reason for exclusion: Sensitivity outcomes provided without corresponding specificity or other 
outcomes of diagnositic test accuracy. 
 
15. Ceroni D, Regusci M, Pazos J, Dayer R and Kaelin A. Acute bone and joint infections in children: 
how much attention should be paid to persistent fever during intravenous antibiotic therapy? Revue 
De Chirurgie Orthopedique Et Reparatrice De L Appareil Moteur 2003; 89(3): 250-256.  
Reason for exclusion: Article written in French, with only abstract in English. 
 
16. Dartnell J, Ramachandran M and Katchburian M. Haematogenous acute and subacute paediatric 
osteomyelitis: A systematic review of the literature. Journal of Bone and Joint Surgery-British Volume 
2012; 94B(5): 584-595.  
Reason for exclusion: Systematic review without raw data for diagnosis test accuracy evaluation. 
 
17. De Boeck H. Osteomyelitis and septic arthritis in children. Acta orthopaedica belgica 2005; 71(5): 
505.  
Reason for exclusion: Summary paper only without raw data for CRP diagnostic accuracy testing. 
 
18. Delaney RA, Lenehan B, O'Sullivan L, McGuinness AJ and Street JT. The limping child: an 
algorithm to outrule musculoskeletal sepsis. Ir J Med Sci 2007; 176(3): 181-187.  
Reason for exclusion: No raw data provided and no case definitions of OA/SA included. 
 
19. Digman JM, Roddy R, Kaczenski A, Godbold S and Abramo T. Evaluation of procalcitonin as a 
negative predictor for serious bacterial infection in pediatrics. Annals of Emergency Medicine 2016; 68 
(4 Supplement 1): S93.  
Reason for exclusion: This article included all serious infections and not possible to extract 
osteoarticular infections. Abstract only format. 
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20. Dubois-FerriSre V, Belaieff W, Lascombes P, de Coulon G and Ceroni D. Transient synovitis of 
the hip: which investigations are truly useful? Swiss medical weekly 2015; 145.  
Reason for exclusion: This paper does not include septic arthritis or osteomyelitis. 
 
21. Ernst AA, Weiss SJ, Tracy LA and Weiss NR. Usefulness of CRP and ESR in predicting septic 
joints. South Med J 2010; 103(6): 522-526.  
Reason for exclusion: Adult data only provided. 
 
22. Gage MJ, Twomey KD, Sala DA, Maguire KJ, Hanstein R, Hennrikus WL, et al. Identifying 
Predictive Factors of Pediatric Septic Arthritis of the Knee in a Lyme Endemic Area. Bulletin of the 
Hospital for Joint Diseases 2018; 76(3): 161-164.  
Reason for exclusion: Study type does not allow extraction of either sensitivity or specificity data for 
CRP. 
 
23. Gandini D. Acute septic arthritis of the hip in children in northern Australia. ANZ J Surg 2003; 
73(3): 136-139.  
Reason for exclusion: Sensitivity data only is provided. 
 
24. García-Arias M, Balsa A and Mola EM. Septic arthritis. Best practice & research Clinical 
rheumatology 2011; 25(3): 407-421. 
Reason for exclusion: Summary paper, no diagnostic test accuracy data available.  
 
25. Gibian JT, Daryoush JR, Wollenman CC, Johnson SR, Henry A, Koehler RJ, et al. The 
Heterogeneity of Pediatric Knee Infections: A Retrospective Analysis. Journal of pediatric orthopedics 
2019.  
Reason for exclusion: Calculation of sensitivity only therefore unable to determine diagnostic 
accuracy 
 
26. Giordano M, Aulisa AG, Guzzanti V, Careri S, Krzysztofiak A and Toniolo RM. Managing of 
musculoskeletal infections in children. Eur Rev Med Pharmacol Sci 2019; 23(2 Suppl): 179-186.  
Reason for exclusion: No raw data provided in this article.  
 
27. Grummert E and Michael K. Pediatric hip pain: Transient synovitis versus septic arthritis. Journal 
of Diagnostic Medical Sonography 2006; 22(3): 185-188.  
Reason for exclusion: Case presentation only 
 
28. Hariharan P and Kabrhel C. Sensitivity of erythrocyte sedimentation rate and C-reactive protein 
for the exclusion of septic arthritis in emergency department patients. J Emerg Med 2011; 40(4): 428-
431.  
Reason for exclusion: Adult patients only presented. 
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29. Harris JC, Caesar DH, Davison C, Phibbs R and Than MP. How useful are laboratory 
investigations in the emergency department evaluation of possible osteomyelitis? Emerg Med 
Australas 2011; 23(3): 317-330.  
Reason for exclusion: Summary information, no raw data provided. 
 
30. Highton E, Perez MG, Cedillo Villamagua C, Sormani MI, Mussini MS, Isasmendi A, et al. 
Osteoarticular infections in a tertiary care children's hospital: Epidemiology and clinical characteristics 
in association with bacteremia. Arch Argent Pediatr 2018; 116(2): e204-e209.  
Reason for exclusion: Article witten in Spanish. 
 
31. Holloway E, Ruffles T and Godden C. Diagnosis and management in the child with suspected 
septic arthritis a 14 year retrospective study and review of the evidence. Archives of Disease in 
Childhood 2011; 96: A62.  
Reason for exclusion: Abstract without raw data and case definitions not provided. 
 
32. Howard A and Wilson M. Easily missed? Septic arthritis in children. BMJ (Online) 2010; 
341(7776): 776-777.  
Reason for exclusion: Letter to the editor. 
 
33. Htun S. Phogenic osteomyelitis of long bones in children. Ann Arbor: The University of Liverpool 
(United Kingdom); 1975. p. 1.  
Reason for exclusion: No test accuracy data. 
  
34. Hugle T, Schuetz P, Mueller B, Laifer G, Tyndall A, Regenass S, et al. Serum procalcitonin for 
discrimination between septic and non-septic arthritis. Clinical and Experimental Rheumatology 2008; 
26(3): 453-456.  
Reason for exclusion: Unable to separate patients 16-18 years from general adult cohort. 
 
35. Inusa BPD, Oyewo A, Brokke F, Santhikumaran G and Jogeesvaran KH. Dilemma in 
Differentiating between Acute Osteomyelitis and Bone Infarction in Children with Sickle Cell Disease: 
The Role of Ultrasound. PLoS ONE 2013; 8(6).  
Reason for exclusion: Variable case definitions included without being clearly defined. 
 
36. Jain S, Tittal P, Rohilla N, Sud A, Yadav C, Kanojia RK, et al. Acute septic arthritis revisited: a 
prospective study in 93 patients correlating C-reactive protein levels with duration of intravenous 
antibiotic therapy, clinical and radiological outcomes. European Journal of Orthopaedic Surgery & 
Traumatology 2009; 19(7): 447-455.  
Reason for exclusion: Case definitions of patients imprecise. 
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37. Jana FN, Ortega CS and Goiano EO. Epidemiological study of osteoarticular infections in 
children. Acta ortopedica brasileira 2018; 26(3): 201-205.  
Reason for exclusion: Includes neonates. 
 
38. Journeau P, Wein F, Popkov D, Philippe R, Haumont T and Lascombes P. Hip septic arthritis in 
children: assessment of treatment using needle aspiration/irrigation. Orthop Traumatol Surg Res 
2011; 97(3): 308-313.  
Reason for exclusion: Not a diagnostic testing assay article. 
 
39. Kallio MJ, Unkila-Kallio L, Aalto K and Peltola H. Serum C-reactive protein, erythrocyte 
sedimentation rate and white blood cell count in septic arthritis of children. Pediatr Infect Dis J 1997; 
16(4): 411-413.  
Reason for exclusion: Sensitivity only provided and unable to calculate diagnostic test accuracy. 
 
40. Kao HC, Huang YC, Chiu C-H, Chang LY, Lee ZL, Chung PW, et al. Acute hematogenous 
osteomyelitis and septic arthritis in children. Journal of microbiology immunology and infection 2003; 
36(4): 260-265.  
Reason for exclusion: Summary data only included in this review. 
 
41. Karambin MM and Hashemian H. Childhood arthritis: Rate of different types. Acta Medica Iranica 
2009; 47(1): 31-34.  
Reason for exclusion: Examined only arthritis, not a diagnostic test paper to evaluate CRP. 
 
42. Kocher MS, Lee B, Dolan M, Weinberg J and Shulman ST. Pediatric orthopedic infections: Early 
detection and treatment. Pediatric Annals 2006; 35(2): 112-122.  
Reason for exclusion: Review article with only summary information. 
 
43. Kocher MS, Mandiga R, Zurakowski D, Barnewolt C and Kasser JR. Validation of a clinical 
prediction rule for the differentiation between septic arthritis and transient synovitis of the hip in 
children. JBJS 2004; 86(8): 1629-1635.  
Reason for exclusion: CRP not included in the analysis. 
 
44. Kopchak O and Kostik M. Differential diagnosis of non-bacterial and acute hemotogenous 
osteomyelitis. Pediatric Rheumatology 2017; 15 (Supplement 2): 102.  
Reason for exclusion: Not diagnostic test evaluation, summary data only included. 
 
45. Krzysztofiak A, Bozzola E, Lancella L, Marchesi A and Villani A. Osteomyelitis in children. Italian 
Journal of Pediatrics Conference: 72th Congress of the Italian Society of Pediatrics Italy 2017; 43(1 
Supplement).  
Reason for exclusion: Summary abstract only, no CRP or procacitonin included. 
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46. Kunnamo I, Kallio P, Pelkonen P and Hovi T. Clinical signs and laboratory tests in the differential 
diagnosis of arthritis in children. Am J Dis Child 1987; 141(1): 34-40.  
Reason for exclusion: Could not exclude neonates in this review. 
 
47. Kuong EE, To M, Chow W, Yuen MH, Choi AKY and Fong CM. Pitfalls in diagnosing septic 
arthritis in hong kong children: Ten years' experience. Hong Kong Medical Journal 2012; 18(6): 482-
487. 
Reason for exclusion: Only included sensitivity data therefore unable to calculate diagnostic accuracy 
parameters. 
 
48. Lalanda M and Alonso JA. Improving the management of the child with an unexplained limp. 
Clinical Governance 2006; 11(4): 308-315.  
Reason for exclusion: Testing algorithim only provided. 
  
49. Lavy CBD. The clinical features and surgical treatment of acute septic arthritis in Malawian 
children. Ann Arbor: University of London, University College London (United Kingdom); 2006. p. 154. 
Reason for exclusion: No diagnostic accuracy test outcomes. 
 
50. Lazzarini L, Mader JT and Calhoun JH. Osteomyelitis in long bones. JBJS 2004; 86(10): 2305-
2318.  
Reason for exclusion: Treatment article in summary format, not diagnostic test accuracy paper. 
 
51. Le Saux N. The diagnosis and treatment of acute osteoarticular infections in children. Paediatrics 
& child health 2018; 23(5): 344-352.  
Reason for exclusion: Article written in French.  
 
52. Lee S, Kim HW, Cho HK, Yun YH, Ryu KH and Kim KH. Clinical presentations and causative 
organisms in children and adolescents with osteoarticular infections: A retrospective study. [Korean]. 
Pediatric Infection and Vaccine 2015; 22(3): 154-163.  
Reason for exclusion: Article written in Korean. 
 
53. Levine MJ, McGuire KJ, McGowan KL and Flynn JM. Assessment of the test characteristics of C-
reactive protein for septic arthritis in children. Journal of pediatric orthopedics 2003; 23(3): 373-377.  
Reason for exclusion: Unable to determine upper or lower age limits of patients included. 
 
54. Lew DP and Waldvogel FA. Osteomyelitis. The Lancet 2004; 364(9431): 369-379.  
Reason for exclusion: Summary review article, no diagnostic test accuracy data. 
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55. Li SF, Cassidy C, Chang C, Gharib S and Torres J. Diagnostic utility of laboratory tests in septic 
arthritis. Emergency Medicine Journal 2007; 24(2): 75-77.  
Reason for exclusion: No CRP or procalcitonin included in this article. 
 
56. Lin Z, Vasudevan A and Tambyah PA. Use of erythrocyte sedimentation rate and C-reactive 
protein to predict osteomyelitis recurrence. J Orthop Surg (Hong Kong) 2016; 24(1): 77-83.  
Reason for exclusion: No cases of acute osteomyelitis. 
 
57. Lorrot M, Fitoussi F, Faye A, Mariani P, Job-Deslandre C, Penneçot G, et al. Laboratory studies in 
pediatric bone and joint infections. Archives de pediatrie: organe officiel de la Societe francaise de 
pediatrie 2007; 14: S86-90.  
Reason for exclusion: Article written in French. 
 
58. Macnicol MF. Patterns of musculoskeletal infection in childhood. Journal of Bone and Joint 
Surgery - Series B 2001; 83(1): 1-2.  
Reason for exclusion: Editorial only. 
 
59. Macnicol MF and Watts AC. Haematogenous osteomyelitis. Surgery (Oxford) 2005; 23(1): 25-30. 
Reason for exclusion: Summary article. 
 
60. Madruga Dias J, Costa MM, Pereira da Silva JA and Viana de Queiroz M. Septic arthritis: patients 
with or without isolated infectious agents have similar characteristics. Infection 2014; 42(2): 385-391.  
Reason for exclusion: Adult cohort of patients. 
 
61. Maharajan K, Patro DK, Menon J, Hariharan AP, Parija SC, Poduval M, et al. Serum Procalcitonin 
is a sensitive and specific marker in the diagnosis of septic arthritis and acute osteomyelitis. J Orthop 
Surg Res 2013; 8: 19.  
Reason for exclusion: Included adults. 
 
62. Mahmoudi S, Pourakbari B, Borhani K, Khodabandeh M, Valian SK, Aziz-Ahari A, et al. Acute 
osteomyelitis and septic arthritis in children: A referral hospital-based study in Iran. Wiener 
Medizinische Wochenschrift 2017; 167(11-12): 259-263. S 
Reason for exclusion:  Sensitivity only provided and unable to extract or calculate diagnostic 
accuracy. 
 
63. Mamishi S, Kalantari N and Pourakbari B. Clinical feature and etiology of septic arthritis and 
osteomyelitis in children in a 10 year period. Acta Medica Iranica 2007; 45(1): 58-62.  
64. Matan AJ and Smith JT. Pediatric septic arthritis. Orthopedics 1997; 20(7): 630-635.  
Reason for exclusion: No CRP or procalcitonin included. 
 
 64 
65. McMahon A-M. Bone and joint infections. Paediatrics and Child Health 2011; 21(12): 546-551. 
Reason for exclusion:Summary article only. 
  
66. Mistry RM, Lennon D, Boyle MJ, Chivers K, Frampton C, Nicholson R, et al. Septic arthritis and 
acute rheumatic fever in children: the diagnostic value of serological inflammatory markers. Journal of 
pediatric orthopedics 2015; 35(3): 318-322.  
Reason for exclusion: Not a diagnostic test accuracy study, recommendations only. 
 
67. Mitchell PD, Viswanath A, Obi N, Littlewood A and Latimer M. A prospective study of screening for 
musculoskeletal pathology in the child with a limp or pseudoparalysis using erythrocyte sedimentation 
rate, C-reactive protein and MRI. J Child Orthop 2018; 12(4): 398-405.  
Reason for exclusion: Included all infections and unable to isolate osteoarticular infections. 
 
68. Monachello Araujo D, Cordero Garcia JM, Garcia Zogby L, Guzman Cruz AJ, Rodado Marina S, 
Coronado Poggio M, et al. Osteomyelitis in children: Association between analytical parameters and 
three-phase bone scan findings. European Journal of Nuclear Medicine and Molecular Imaging 2018; 
45 (Supplement 1): S350.  
Reason for exclusion:Abstract without raw data for analysis. 
 
69. Moro-Lago I, Talavera G, Moraleda L and Gonzalez-Moran G. Clinical presentation and treatment 
of septic arthritis in children. Revista espanola de cirugia ortopedica y traumatologia 2017; 61(3): 170-
175.  
Reason for exclusion: Article written in Spanish text. 
 
70. Nannery R and Heinz P. Approach to joint pain in children. Paediatrics and Child Health (United 
Kingdom) 2018; 28(2): 43-49.  
Reason for exclusion: Summary article. 
 
71. Paakkonen M, Kallio MJ, Kallio PE and Peltola H. Sensitivity of erythrocyte sedimentation rate 
and C-reactive protein in childhood bone and joint infections. Clin Orthop Relat Res 2010; 468(3): 
861-866.  
Reason for exclusion: Sensitivity data only provided and unable to calculate diagnostic accuracy test 
performance. 
 
72. Paakkonen M, Kallio MJ, Kallio PE and Peltola H. C-reactive protein versus erythrocyte 
sedimentation rate, white blood cell count and alkaline phosphatase in diagnosing bacteraemia in 
bone and joint infections. J Paediatr Child Health 2013; 49(3): E189-192.  




73. Patel L, Michael J, Schroeder L, Sherman AK, Berglund L and Newland JG. Can a Septic Hip 
Decision Rule Aid in the Evaluation of Suspected Pediatric Musculoskeletal Infections? J Emerg Med 
2019; 56(3): 241-247.  
Reason for exclusion: Included all musculoskeletal infections. 
 
74. Peltola H, Vahvanen V and Aalto K. Fever, C-reactive protein, and erythrocyte sedimentation rate 
in monitoring recovery from septic arthritis: a preliminary study. Journal of pediatric orthopedics 1984; 
4(2): 170-174.  
Reason for exclusion: Markers used to monitor the effectiveness of treatment only. 
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